



Urine Drug Analysis

Test No. 24-5671 Summary Report

Each sample set contained urine samples from four individual cases with unique scenarios. Participants were asked to analyze the urine samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used. Data were returned from 119 participants and are compiled into the following tables:

	<u>Page</u>
<u>Manufacturer's Information</u>	<u>2</u>
<u>Summary Comments</u>	<u>3</u>
<u>Table 1: Item 1 Results</u>	<u>4</u>
<u>Table 2: Item 2 Results</u>	<u>26</u>
<u>Table 3: Item 3 Results</u>	<u>50</u>
<u>Table 4: Item 4 Results</u>	<u>70</u>
<u>Table 5: Additional Comments</u>	<u>95</u>
<u>Report Appendix: Data Sheet</u>	<u>96</u>

This report contains the data received from the participants in this test. Since these participants are located in many countries around the world, and it is their option how the samples are to be used (e.g., training exercise, known or blind proficiency testing, research and development of new techniques, etc.), the results compiled in the Summary Report are not intended to be an overview of the quality of work performed in the profession and cannot be interpreted as such. The Summary Comments are included for the benefit of participants to assist with maintaining or enhancing the quality of their results. These comments are not intended to reflect the general state of the art within the profession.

Participant results are reported using a randomly assigned "WebCode". This code maintains participant's anonymity, provides linking of the various report sections, and will change with every report.

Manufacturer's Information

Each sample set consisted of four urine samples from cases with unique scenarios. Participants were asked to analyze the contents of each sample using their existing protocols and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used.

SAMPLE PREPARATION: The urine used in this test was from the same lot, which tested negative for a panel of common drugs and controlled substances. A stock solution of each chosen drug was used to spike each item. Items were prepared at separate times with different glassware.

ITEMS 1, 2, 3 and 4 (PREPARATION): Sample preparation consisted of adding a predetermined amount of drug stock solution to a beaker containing human urine, where the equivalent of 2% w/v sodium fluoride was added and then stirred. A 50 mL aliquot of the mixture was then transferred into each of the pre-labeled specimen cups. All cups were placed in a refrigerator immediately after production and remained there until the sample sets were prepared.

VERIFICATION: Predistribution results were consistent with each other and the manufacturer's preparation information.

SAMPLE SET ASSEMBLY: Once verification was completed, each sample set was assembled with an Item 1, 2, 3, and 4 then placed into a Department of Transportation regulated shipping container. Sample sets were returned to the refrigerator until shipment.

Item 1 Drug	Item 2 Drug	Item 3 Drug	Item 4 Drug
Zolpidem (80 ng/mL)	Noroxycodone (400 ng/mL)	Diphenhydramine (50 ng/mL)	Oxazepam (120 ng/mL)
Zolpidem Carboxylic Acid (180 ng/mL)	Oxycodone (200 ng/mL)		Temazepam (80 ng/mL)
	Oxymorphone (100 ng/mL)		Acetaminophen (70 ng/mL)

Please note that the preparation concentration is the value used for calculations during the test preparation phase and may not necessarily represent the final concentration of the samples. It is advised to view the Grand Mean statistics available in this Summary Report as well as wait for the Individual Reports before evaluating performance.

Summary Comments

This test was designed to allow participants to assess their proficiency in the examination for the presence and concentration of drugs and/or metabolites in urine. The sample sets provided to participants contained four urine samples from individual cases with unique scenarios. Each of the four urine specimens were spiked with varying concentrations of specific drugs and/or metabolites in case-like ranges. Refer to the Manufacturer's Information for preparation details.

A total of 119 participants returned data for this test. For Item 1, 113 participants reported screening results. The most commonly reported screening result was the presence of zolpidem by 81 participants. Thirty-one participants indicated that no drugs were detected utilizing screening methods. Of the 102 participants that reported confirmatory results, 98 participants reported the presence of zolpidem and five participants reported the presence of zolpidem carboxylic acid.

Of the 110 participants that reported screening results for Item 2, 69 participants reported the presence of oxycodone, 28 reported the presence of oxymorphone, 10 reported noroxycodone, and 11 reported the presence of opioids. Thirty-five participants indicated that no drugs were detected utilizing screening methods. Of the 84 participants who reported confirmatory results, 77 reported the presence of oxycodone, 40 reported oxymorphone, and 20 reported noroxycodone.

Of the 108 participants who reported screening results for Item 3, the most commonly reported was the presence of diphenhydramine by 54 participants. Forty-seven participants indicated that no drugs were detected utilizing screening methods. Of the 86 participants who reported confirmatory results, 68 reported diphenhydramine, and 16 indicated that no drugs nor metabolites were detected utilizing confirmatory methods. Some participants noted in the Item 3 Additional Comments section the detection of diphenhydramine, but this was not reflected in the confirmatory or screening response summaries. Participants reporting "No drugs nor metabolites detected" are not highlighted as inconsistent due to differing laboratory reporting policies on the presence of diphenhydramine which is not listed in the 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act.

Of the 106 participants that reported screening results for Item 4, 43 reported the presence of oxazepam, 45 reported temazepam, and 68 reported the presence of benzodiazepines. Of the 95 participants who reported confirmatory results, 89 reported the presence of oxazepam and 89 reported temazepam.

For all four items, immunoassay was the most commonly reported screening method. GC/MS and LC/MS/MS were the most commonly reported confirmatory methods used to analyze the samples.

If a participant indicated that the confirmatory quantitative result was a single determination and it was reported in ng/mL, the conclusive quantitative result was included in the raw data table. Due to the low number of participants who reported quantitative data, statistical analysis has not been provided.

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
8JQ3YD	Zolpidem
8MA3D8	Zolpidem
8PFKB4	No drugs detected utilizing screening methods.
8R8JP2	Zolpidem, Amphetamine
8V7UL2	Benzoyllecgonine, Zolpidem, Amphetamine
9CNDTT	zolpidem
9FBVBD	zolpidem
9J4WB8	No drugs detected utilizing screening methods.
9YZBBZ	amphetamine, zolpidem
A2LEJX	Zolpidem
A3DB8R	No drugs detected utilizing screening methods.
AAWG6Y	Zolpidem
AQ24A7	Zolpidem
B47LK7	zolpidem
BMJ7EN	No drugs detected utilizing screening methods.
BRWNW7	No drugs detected utilizing screening methods.
C2GEW3	Zolpidem
C6GQR3	Zolpidem
CDAU3R	Zolpidem
CW4WEL	Zolpidem
D4H3NX	Zolpidem
D8XACX	Benzoyllecgonine and Zolpidem
DBYE76	zolpidem
DTH8U9	zolpidem
E4WNZK	Zolpidem
EMMZP6	Zolpidem (ELISA)
F2M227	Zolpidem
FDTEUR	Zolpidem

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
FFKAJK	Zolpidem
FJ7R27	zolpidem
FJKHMV	Zolpidem
FXZJL	No drugs detected utilizing screening methods.
GCF2RF	zolpidem
GH8RAR	Zolpidem
GLTTJY	Zolpidem
HDTXUY	Zolpidem
HPMAAX	zolpidem
JFTLPF	No drugs detected utilizing screening methods.
JHGTDH	Zolpidem
KEEE4X	zolpidem
KN3AZT	Zolpidem
KVJLHZ	No drugs detected utilizing screening methods.
LLPZML	zolpidem
LNGVCF	No drugs detected utilizing screening methods.
MKDKTK	Zolpidem
MNENMT	zolpidem
MYW6FZ	Zolpidem
N8JLLF	Zolpidem
NFETXT	Zolpidem Phenyl-4-carboxylic acid
NH3ZMW	Zolpidem
NHHJ8U	zolpidem
NP3JKL	Amphetamine and Zolpidem
PBFT2A	No drugs detected utilizing screening methods.
PE2BJU	No drugs detected utilizing screening methods.
PFV2P9	No drugs detected utilizing screening methods.
PQVR9V	ELISA Zolpidem

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
PRMQLU	No drugs detected utilizing screening methods.
PVL2HU	No drugs detected utilizing screening methods.
Q9PRTZ	No drugs detected utilizing screening methods.
QEVNEL	Methamphetamine Zolpidem
QVZVUM	Zolpidem
QYFH8T	zolpidem
R22LFQ	zolpidem
R4N7GN	No drugs detected utilizing screening methods.
R8P7J7	No drugs detected utilizing screening methods.
RBCN2Q	Zolpidem
RU3ZQB	Zolpidem
T3QENE	Zolpidem
T3VRCB	No drugs detected utilizing screening methods.
T6HBD9	Zolpidem
T7U38A	No drugs detected utilizing screening methods.
TF2K4M	Zolpidem
U82PEM	No drugs detected utilizing screening methods.
U9DG9P	Zolpidem
UCWGMK	zolpidem zolpidem phenyl-4-carboxylic acid
UZHJHF	Zolpidem
V4XAKQ	Zolpidem
VBJ8AD	Zolpidem
VR3ZXG	Methamphetamine Zolpidem
W68H9G	Zolpidem
WZCR36	No drugs detected utilizing screening methods.
XCZBUF	zolpidem

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
XE9KQJ	Zolpidem
XHQK4D	zolpidem
XJZPJM	zolpidem
XPQZUL	Zolpidem
XZ7U6E	No drugs detected utilizing screening methods.
YJEF4R	Zolpidem
ZA74PA	Benzoylcegonine Zolpidem
ZFFKXX	No drugs detected utilizing screening methods.

Screening Response Summary for Item 1	Participants: 113
Zolpidem:	81
Zolpidem Carboxylic Acid:	2
Other Drugs Detected:	12
No Drugs Detected Utilizing Screening Methods:	31

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 1

TABLE 1B

Item Scenario:

A 49 year old female was pulled over in the early morning for swerving between lanes. The officer noted slowed speech and drowsiness. A urine sample was collected for analysis two hours later.

Item Contents and Preparation Concentration: Zolpidem (80 ng/mL)
Zolpidem Carboxylic Acid (180 ng/mL)

What drugs/metabolites were detected in Item 1?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
29UQKC	Zolpidem	✓			
2D7UBE	Zolpidem	✓			
2G4FXB	Zolpidem	✓			
33K6QZ	Zolpidem	✓			
372DEY	Zolpidem	✓			
3R2FBF	Zolpidem	✓			
3V4EL9	Zolpidem	✓			
46ZY6C	Zolpidem	✓			
47VKRB	Zolpidem	✓			
4KGYVB	Zolpidem	✓			
4M67KD	zolpidem	✓			
62FC4C	Zolpidem	✓			
	Zolpidem phenyl-4-carboxylic acid	✓			
6XGXJ8	Zolpidem	✓			
76EARA	Zolpidem	✓			
7HMTQ4	Zolpidem	✓			
7QHQGD	Zolpidem	✓			
8A4698	Zolpidem	✓			
8DL4L3	zolpidem		0.081		mg/l
8JQ3YD	Zolpidem	✓			
8MA3D8	Zolpidem	✓			
8PFKB4	Zolpidem	✓			
8R8JP2	Zolpidem		117	26	ng/mL
8V7UL2	Zolpidem		86	19	ng/mL
9CNDTT	zolpidem	✓			
9FBVBD	zolpidem	✓			
9J4WB8	Zolpidem	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
9YZBBZ	Zolpidem	✓			
A2LEJX	Zolpidem	✓			
A3DB8R	caffene	✓			
	Resorinol	✓			
	Tryptamine	✓			
	Tryptophol	✓			
AAWG6Y	Zolpidem	✓			
AQ24A7	Zolpidem	✓			
ATNMB4	Zolpidem	✓			
B47LK7	zolpidem	✓			
BRWNW7	zolpidem	✓			
C2GEW3	Zolpidem	✓			
C6GQR3	Zolpidem	✓			
CDAU3R	Zolpidem	✓			
CW4WEL	Zolpidem	✓			
D4H3NX	Zolpidem	✓			
D7KVNN	Zolpidem phenyl-4-carboxylic acid	✓			
D8XACX	Zolpidem	✓			
	Benzoylcegonine	✓			
DBYE76	zolpidem	✓			
DTH8U9	zolpidem	✓			
E4WNZK	zolpidem	✓			
EMMZP6	Zolpidem	✓			
F2M227	Zolpidem	✓			
FDTEUR	Zolpidem	✓			
FFKAJK	Zolpidem		74.8	6.0	ng/mL
FJ7R27	zolpidem	✓			
FJKHMV	Zolpidem	✓			
FXZJLL	caffen	✓			
	Tryptamine	✓			
	Tryptophol	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
GCF2RF	zolpidem	✓			
GH8RAR	Zolpidem	✓			
GLTTJY	Zolpidem	✓			
HDTXUY	Zolpidem	✓			
HPMAAX	zolpidem	✓			
JHGTDH	Zolpidem	✓			
KEEE4X	zolpidem	✓			
KN3AZT	Zolpidem	✓			
KVJLHZ	Zolpidem	✓			
LLPZML	zolpidem	✓			
LZ8RCT	Zolpidem	✓			
MKDGTK	Zolpidem	✓			
	Zolpidem phenyl-4-carboxylic acid	✓			
MNENMT	zolpidem	✓			
MYW6FZ	Zolpidem	✓			
N8JLLF	Zolpidem	✓			
NFETXT	Zolpidem Phenyl-4-carboxylic acid	✓			
NH3ZMW	Zolpidem	✓			
NHHJ8U	zolpidem	✓			
PE2BJU	zolpidem	✓			
PQVR9V	Zolpidem	✓			
PRMQLU	zolpidem	✓			
PTZKZ9	Zolpidem	✓			
PVL2HU	zolpidem	✓			
QAZUGK	Zolpidem	✓			
QEVNEL	Zolpidem	✓			
QJBV3K	Zolpidem	✓			
QVZVUM	Zolpidem	✓			
QYFH8T	zolpidem	✓			
R22LFQ	zolpidem	✓			
R4N7GN	Zolpidem	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?				
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty Units
R8P7J7	Zolpidem	✓		
RBCN2Q	Zolpidem	✓		
RU3ZQB	Zolpidem	✓		
T3QENE	Zolpidem	✓		
T6HBD9	Zolpidem	✓		
T7U38A	zolpidem	✓		
TF2K4M	Zolpidem	✓		
U9DG9P	Zolpidem	✓		
UCWGMK	zolpidem	✓		
	zolpidem phenyl-4-carboxylic acid	✓		
UZHJHF	Zolpidem	✓		
V4XAKQ	Zolpidem	✓		
VBJ8AD	Zolpidem	✓		
VR3ZXG	Zolpidem	✓		
W68H9G	Zolpidem	✓		
XCZBUF	zolpidem	✓		
XE9KQJ	Zolpidem	✓		
XHQK4D	zolpidem	✓		
XJZPJM	zolpidem	✓		
XPQZUL	Zolpidem	✓		
YJEF4R	Zolpidem	✓		
ZA74PA	Zolpidem	✓		

Confirmatory Response Summary for Item 1		Participants: 102
Zolpidem: 98		
Zolpidem Carboxylic Acid: 5		
Other Identified Drugs/Metabolites: 8		
No Drugs/Metabolites Detected Utilizing Confirmatory Methods: 0		

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 1

TABLE 1C

Item 1 Raw Data - Zolpidem
Preparation concentration: 80 ng/mL

WebCode	List of Raw Data determinations (ng/mL)	
8R8JP2	117.00	130.00
8V7UL2	88.690	86.990
FFKAJK	74.800	

Statistical Analysis for Item 1 - Zolpidem

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

TABLE 1C: Raw Data - Item 1
Item 1 Raw Data - Zolpidem Carboxylic Acid
Preparation concentration: 180 ng/mL

WebCode List of Raw Data determinations (ng/mL)

No Raw Data results were reported for this Drug/Analyte for Item 1.

Statistical Analysis for Item 1 - Zolpidem Carboxylic Acid

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

Reporting Procedures - Item 1

TABLE 1D - Item 1

WebCode	Quantitative Reporting Procedures
---------	-----------------------------------

8DL4L3	A single determination.
8R8JP2	Lowest of duplicate samples, truncated
8V7UL2	The lowest of the duplicates
FFKAJK	A single determination.

Response Summary for Item 1	Participants: 4
-----------------------------	-----------------

A single determination:	2 (50.0%)
The mean of duplicate/several determinations:	0 (0.00%)
Other:	2 (50.0%)

Methods of Analysis - Item 1

TABLE 1E - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
29UQKC	Immunoassay GC/MS	✓ ✓	✓	
2D7UBE	LC-QTOF-MS LC/MS/MS	✓	✓	
2G4FXB	Immunoassay GC/MS	✓ ✓	✓	
33K6QZ	LC/MS/MS	✓	✓	
372DEY	LC/MS/MS	✓	✓	
3AL8AE	Immunoassay	✓		
3DY877	Immunoassay	✓		
3R2FBF	Immunoassay LC/MS/MS	✓	✓	
3V4EL9	LC-QTOF-MS	✓	✓	
46ZY6C	LC-QTOF GC/MS Immunoassay	✓ ✓ ✓	✓	
47VKRB	Immunoassay GC/MS LC/MS/MS LC-QTOF	✓ ✓ ✓	✓ ✓	
4KGYVB	Immunoassay LC/MS/MS GC/NPD GC/MS	✓ ✓	✓ ✓	
4M67KD	LC/MS/MS GC/MS Immunoassay	✓	✓ ✓	
62FC4C	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
6XGXJ8	LC-QTOF-MS LC/MS/MS	✓	✓	
74HP6A	Immunoassay	✓		
76EARA	Immunoassay GC/MS	✓	✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
7HMTQ4	LC/MS LC/MS/MS	✓	✓	
7QHQGD	Immunoassay LC/MS/MS GC/MS	✓ ✓	✓ ✓	
7RCGMR	GC/MS	✓		
7T6AHB	Immunoassay	✓		
8A4698	LC/MS/MS	✓	✓	
8DL4L3	LC/MS/MS			✓
8JQ3YD	Immunoassay GC/MS	✓	✓	
8MA3D8	Immunoassay GC/MS	✓ ✓	✓	
8PFKB4	GC/MS	✓	✓	
8R8JP2	Immunoassay LC/MS/MS	✓	✓	✓
8V7UL2	Immunoassay LC/MS/MS	✓	✓	✓
9CNDTT	LC/MS/MS	✓	✓	
9FBVBD	GC/MS LC-HRMS/MS	✓ ✓	✓ ✓	
9J4WB8	Immunoassay LC/MS/MS	✓	✓	
9YZBBZ	Immunoassay GC/MS	✓	✓	
A2LEJX	Immunoassay GC/MS	✓ ✓	✓	
A3DB8R	GC/MS	✓	✓	
AAWG6Y	Immunoassay GC/MS	✓ ✓	✓	
AQ24A7	Immunoassay GC/MS	✓	✓	
ATNMB4	GC/MS		✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
B47LK7	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
BMJ7EN	Immunoassay	✓		
BRWNW7	LC/MS/MS		✓	
	Immunoassay	✓		
C2GEW3	Immunoassay	✓		
	GC/MS	✓	✓	
C6GQR3	Immunoassay	✓		
	GC/MS	✓	✓	
CDAU3R	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
CW4WEL	LC-QTOF-MS	✓	✓	
D4H3NX	Immunoassay	✓		
	GC/MS	✓	✓	
D7KVNN	LC-QTOF		✓	
D8XACX	LC/MS/MS	✓	✓	
	GC/MS		✓	
	Rapid Chromatographic Immunoassay	✓		
DBYE76	LC-HRMS/MS	✓	✓	
DTH8U9	LC-HRMS/MS	✓	✓	
	GC/MS		✓	
E4WNZK	Immunoassay	✓		
	LC-QTOF	✓		
	GC/MS		✓	
	LC-QTOF		✓	
EMMZP6	Immunoassay	✓		
	GC/MS	✓	✓	
F2M227	Immunoassay	✓		
	LC/MS/MS		✓	
FDTEUR	Immunoassay	✓		
	GC/MS	✓	✓	
FFKAJK	LC/MS/MS	✓	✓	✓
FJ7R27	LC-HRMS/MS	✓		
	GC/MS		✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
FJKHMV	Immunoassay GC/MS	✓ ✓	✓	
FXZJL	GC/MS	✓	✓	
GCF2RF	GC/MS LC/MS/MS LC-QTOF-MS Immunoassay	✓ ✓	✓ ✓	
GH8RAR	LC-QTOF LC/MS/MS	✓	✓	
GLTTJY	Immunoassay LC/MS/MS GC/MS	✓	✓ ✓	
HDXUY	LC/MS/MS	✓	✓	
HPMAAX	LC-QTOF-MS LC/MS/MS	✓	✓	
JFTLPF	Immunoassay	✓		
JHGTDH	Immunoassay GC/MS	✓	✓	
KEEE4X	Immunoassay LC/MS/MS GC/MS	✓ ✓ ✓	✓ ✓	
KN3AZT	Immunoassay GC/MS	✓ ✓	✓	
KVJLHZ	Immunoassay GC/MS	✓	✓	
LLPZML	Immunoassay GC/MS	✓ ✓	✓	
LNGVCF	Immunoassay	✓		
LZ8RCT	GC/MS		✓	
MKDGTK	Immunoassay LC/MS/MS	✓	✓	
MNENMT	GC/MS LC/MS/MS	✓ ✓	✓	
MYW6FZ	Immunoassay LC/MS/MS	✓	✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
N8JLLF	LC-QTOF-MS	✓		
	Immunoassay	✓		
	GC/MS		✓	
NFETXT	Immunoassay LC-QTOF	✓	✓	
NH3ZMW	Immunoassay LC/MS/MS	✓	✓	
NHHJ8U	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
NP3JKL	Immunoassay	✓		
PBFT2A	Immunoassay	✓		
PE2BJU	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
PFV2P9	Immunoassay	✓		
PQVR9V	Immunoassay	✓		
	GC/MS		✓	
PRMQLU	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
PTZKZ9	GC/MS		✓	
PVL2HU	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
Q9PRTZ	Immunoassay	✓		
QAZUGK	GC/MS		✓	
QEVNEL	LC-QTOF-MS	✓		
	LC/MS/MS		✓	
QJBV3K	GC/MS		✓	
QVZVUM	Immunoassay	✓		
	GC/MS	✓	✓	
QYFH8T	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
	Immunoassay	✓		

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
R22LFQ	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
R4N7GN	Immunoassay	✓		
	LC-QTOF-MS		✓	
	GC/MS		✓	
R8P7J7	LC/MS/MS	✓	✓	
RBCN2Q	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
RU3ZQB	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
T3QENE	Immunoassay	✓		
	GC/MS	✓	✓	
T3VRCB	Immunoassay	✓		
T6HBD9	LC/MS/MS	✓	✓	
T7U38A	Immunoassay	✓		
	GC/MS		✓	
TF2K4M	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
U82PEM	Immunoassay	✓		
U9DG9P	Immunoassay	✓		
	LC/MS/MS		✓	
UCWGMK	LC/MS/MS	✓	✓	
UZHJHF	LC/MS	✓	✓	
V4XAKQ	LC-HRMS/MS	✓	✓	
VBJ8AD	Immunoassay	✓		
	GC/MS	✓	✓	
VR3ZXG	LC-QTOF-MS	✓		
	LC/MS/MS		✓	
W68H9G	Immunoassay	✓		
	GC/MS	✓	✓	
WZCR36	Immunoassay	✓		

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
XCZBUF	Immunoassay GC/MS	✓ ✓	✓	
XE9KQJ	Immunoassay LC/MS/MS GC/MS	✓ ✓	✓ ✓	
XHQK4D	LC/MS/MS GC/MS	✓	✓	
XJZPJM	hrams GC/MS	✓	✓	
XPQZUL	Immunoassay LC/MS GC/MS	✓	✓ ✓	
XZ7U6E	Immunoassay	✓		
YJEF4R	LC/MS/MS	✓	✓	
ZA74PA	LC/MS/MS	✓	✓	
ZFFKXX	Immunoassay	✓		

Response Summary for Item 1 - Methods of Analysis			Participants: 119
	Screening	Confirmatory	Quantitation
Immunoassay:	78	0	0
GC/MS:	33	65	0
LC/MS:	2	2	0
LC/MS/MS:	23	47	4
Other:	23	11	0

Additional Comments for Item 1

TABLE 1F

WebCode	Item Comments
29UQKC	Drug screen: screening/confirmation - Promazine - internal standard
2G4FXB	Promazine (ISTD) - Drug Screen for Urine
3AL8AE	Creatinine normal
3R2FBF	The cut-off value of zolpidem is 25 ng/mL for LC/MS/MS
3V4EL9	Estazolam was used as internal standard
4M67KD	Internal standard-mepivacaine. zolpidem limit of detection=0.025 mg/L
6XGXJ8	Zolpidem LOD set at 5 ng/mL
74HP6A	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP.
7RCGMR	Liquid-liquid extraction (H+/OH-) with DCM followed by derivatisation with BSTFA
7T6AHB	Creatinine normal
8MA3D8	Promazine was used as an internal standard.
8R8JP2	Basic Drug screen ran as a result of Amphetamine presumptive positive came back not detected. The item was analyzed for the following drugs utilizing the listed methods: Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoyllecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem. Basic Drug Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: amphetamine, diphenhydramine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, LSD. Qualitatively: ephedrine/pseudoephedrine, psilocin. Benzodiazepines Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: 7-aminoclonazepam, alprazolam, chlordiazepoxide, clonazepam, diazepam, flunitrazepam, lorazepam, nordiazepam, oxazepam, temazepam, zolpidem Qualitatively: 7-aminoflunitrazepam, estazolam, etizolam, midazolam, nitrazepam, triazolam, zopiclone
8V7UL2	This sample screened presumptive positive for benzoyllecgonine, however our laboratory is not currently able to confirm this compound. Therefore, confirmatory testing for benzoyllecgonine was not performed. This sample screened presumptive positive for amphetamine and confirmatory testing was performed, however this analyte was not detected. The limit of quantitation for amphetamine is 5 ng/mL.
9CNDTT	screening performed 4/3/24, confirmatory testing on 4/5/24
9FBVBD	Internal standard - Mepivacaine. Artifacts - caffeine
9J4WB8	The Internal standard was used is Codeine D3
9YZBBZ	Confirmatory ISTD: NPA and SKF
AQ24A7	Internal Standards used for GC-MS were methaqualone and barbital. Caffeine was not reported due to being present in the extracted blank and positive control.
ATNMB4	Internal standard: Flurazepam. Sample preparation: L/L extraction. The final extract is derivatized with BSTFA and analyzed by GC/MS
B47LK7	Internal Standard GC/MS & LC/MS/MS: mepivacaine
CDAU3R	Mepivacaine - Internal standard for QTOF and GCMS.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
CW4WEL	IS: Triazolam-D4; LOD: 10 ng/mL.
D8XACX	iCassette (THC) test device was used to screen for THC, referred to in 1-5 as rapid Chromatographic immunoassay.
DBYE76	IS: mepivacaine, mephobarbital
DTH8U9	LC-HRMS/MS internal standards: mepivacaine, mephobarbital. GC/MS internal standard: mepivacaine
EMMZP6	Hexobarbital, n-Propylamphetamine, and Mepivacaine were used as GC/MS internal standards.
FFKAJK	Panel includes only the following analytes: Cyclobenzaprine, Imipramine, Mitragynine, Zolpidem, Phencyclidine
FXZJLL	- Acetonitrile was detected in the urine sample by (GCMS-HS). Following chemical compounds were also observed: - Caffeine, - Carvacol derivative, - 7-Hydroxy-3-(1H-imidazole-4-yl) derivative, - Resorcinol, - Ethyl-3-indoleacetate
HDTXUY	Quantitative analysis not performed due to lack of reference material.
KEEE4X	Internal Standard: Mepivacaine
KN3AZT	Internal Standards used: Promazine.
LNGVCF	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP-1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
MKDKTK	Zolpidem Internal Standard: Zolpidem-D6, Limit of Detection: 5 ng/mL; Zolpidem phenyl-4-carboxylic acid Internal Standard: Zolpidem-D6; Limit of Detection: 5 ng/mL
N8JLLF	Internal Standard = Mepivacaine
NFETXT	Targeted analysis for Zolpidem was conducted using LCMSMS and the result was negative. Additionally, Zolpidem was not detected using LC-QTOF and only its metabolite (Zolpidem Phenyl-4-carboxylic acid) was detected. Quantitative analysis could not be conducted as our laboratory do not have this analyte as CRM.
NHHJ8U	Internal Standard: Mepivacaine
NP3JKL	This screened presumptive positive for amphetamine and zolpidem. However, I am not qualified to confirm the presence of these two substances. The immunoassay tests for the following drugs: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem
PE2BJU	Mepivacaine was used for internal standard in GC/MS and LC/MS/MS methods.
PFV2P9	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP-1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
PQVR9V	N-Propylamphetamine, Mepivacaine, and Hexobarbital were used as Internal Standards.
PRMQLU	mepivacaine used as internal standard
PTZKZ9	Internal Standard: SKF-525A
PVL2HU	mepivacaine used as internal standard for gcms and lcms analysis
QAZUGK	Internal standard: Flurazepam
QEVNEL	Methamphetamine LOD set at 50 ng/mL. Zolpidem LOD set at 5 ng/mL

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
QJBV3K	Tetracosane is the internal standard
QVZVUM	Internal standard used for drug screen was promazine.
QYFH8T	Internal Standard - mepivacaine
R22LFQ	Internal standard: mepivacaine
RBCN2Q	Internal Standard-Mepivacaine/Nalorphine, Mepivacaine
RU3ZQB	Internal Standard used was Mepivacaine
TF2K4M	internal standard=mepivacaine
V4XAKQ	Mepivacaine and Mephobarbital used as internal standards.
VR3ZXG	Methamphetamine LOD set at 50 ng/mL. Zolpidem LOD set at 5 ng/mL
W68H9G	Promazine used as internal standard for GC/MS screening and confirmatory analysis.
WZCR36	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
XCZBUF	ISTD - phenyltoloxamine
XE9KQJ	internal standard: mepivacaine
XJZPJM	HRAMS i.s. mepivacaine. GCMS i.s. mepivacaine
XPQZUL	Internal Standard" Mepivacaine
XZ7U6E	Chemiluminescence Immunoassay screening technique. Urine screening includes the following at specified cutoffs: Fentanyl 2ng/ml, ABPINACA 2.5ng/ml, Methamphetamine 200ng/ml, Barbiturates 200ng/ml, Benzodiazepines 150ng/ml, Methadone 300ng/ml, Opiates 200ng/ml, Benzoyllecgonine 150ng/ml, Oxycodone 50ng/ml, Tramadol 5ng/ml, THC 20ng/ml, TCA 150ng/ml, Amphetamine 200ng/ml, Buprenorphine 1ng/ml, 6MAM 10ng/ml, JWH-018 20ng/ml, Alpha PVP 5ng/ml, UR 144 10ng/ml
YJEF4R	Zolpidem LOD 5ng/ml; ISTD Zolpidem-d6
ZA74PA	Zolpidem: ISTD Zolpidem-d6; LOD 5ng/mL
ZFFKXX	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.

Screening Results - Item 2

TABLE 2A

Item Scenario:

A 26 year old male was arrested for attempted robbery of a local drug store. Upon arrest he displayed agitated behavior and was sweating profusely. Urine was collected within 4 hours of arrest.

Item Contents and Preparation Concentration: Oxycodone (200 ng/mL)
Oxymorphone (100 ng/mL)
Noroxycodone (400 ng/mL)

WebCode	Screening Results
29UQKC	No drugs detected utilizing screening methods.
2D7UBE	Oxycodone Noroxycodone Oxymorphone Acetaminophen 25H-NBOMe
2G4FXB	No drugs detected utilizing screening methods.
33K6QZ	Opiates
372DEY	Oxycodone, oxymorphone
3AL8AE	Oxycodone
3DY877	Amphetamine, Oxycodone/Oxymorphone
3R2FBF	oxycodone
3V4EL9	Oxycodone Noroxycodone Oxymorphone
46ZY6C	Oxycodone Oxycodone metabolite
47VKRB	Oxycodone Noroxycodone
4KGYVB	Oxycodone
4M67KD	No drugs detected utilizing screening methods.
62FC4C	No drugs detected utilizing screening methods.
6XGXJ8	Oxycodone Oxymorphone
74HP6A	No drugs detected utilizing screening methods.
76EARA	opioid - oxycodone
7HMTQ4	Oxycodone Oxymorphone

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
7QHQQD	Oxycodone
7RCGMR	No drugs detected utilizing screening methods.
7T6AHB	Oxycodone
8A4698	Oxycodone Oxymorphone
8DL4L3	Oxycodone Oxymorphone
8JQ3YD	Randox Evidence Investigator drug categories: Oxy 1, Oxy 2, & OPDS. Dates performed: 4/10/24, 4/16/24, 4/18/24.
8MA3D8	No drugs detected utilizing screening methods.
8PFKB4	No drugs detected utilizing screening methods.
8R8JP2	Oxycodone/Oxymorphone, Amphetamine
8V7UL2	Benzoylcegonine, Oxycodone/oxymorphone, Amphetamine
9CNDTT	oxycodone, noroxycodone, oxymorphone
9FBVBD	oxycodone
9J4WB8	No drugs detected utilizing screening methods.
9YZBBZ	opiates, oxycodone/oxymorphone,
A2LEJX	No drugs detected utilizing screening methods.
A3DB8R	No drugs detected utilizing screening methods.
AAWG6Y	No drugs detected utilizing screening methods.
B47LK7	oxycodone
BMJ7EN	Oxycodone
BRWNW7	No drugs detected utilizing screening methods.
C2GEW3	No drugs detected utilizing screening methods.
C6GQR3	No drugs detected utilizing screening methods.
CDAU3R	Noroxycodone Oxycodone Oxymorphone
CW4WEL	Oxycodone, Noroxycodone, Oxymorphone
D4H3NX	No drugs detected utilizing screening methods.

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
D8XACX	Oxymorphone and oxycodone
DBYE76	oxycodone
DTH8U9	oxycodone
E4WNZK	Oxycodone 1 Oxycodone 2 Opioids
EMMZP6	Oxycodone/Oxymorphone (ELISA)
F2M227	Opiates
FDTEUR	No drugs detected utilizing screening methods.
FFKAJK	No drugs detected utilizing screening methods.
FJ7R27	oxycodone
FJKHMV	No drugs detected utilizing screening methods.
FXZJL	No drugs detected utilizing screening methods.
GH8RAR	Oxymorphone Oxycodone
GLTTJY	Opiates
HDTXUY	Oxycodone, Oxymorphone
HPMAAX	oxycodone, oxymorphone, noroxycodone
JFTLPF	No drugs detected utilizing screening methods.
JHGTDH	Oxycodone
KEEE4X	Oxycodone
KN3AZT	No drugs detected utilizing screening methods.
KVJLHZ	Oxycodone
LLPZML	No drugs detected utilizing screening methods.
LNGVCF	Oxycodone
MKDKTK	Oxycodone
MNENMT	oxycodone
MYW6FZ	Opiates
NFETXT	Oxycodone

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
NH3ZMW	Oxycodone 1 Oxycodone 2
NHHJ8U	Oxycodone
NP3JKL	Amphetamine and oxycodone/oxymorphone
PBFT2A	No drugs detected utilizing screening methods.
PE2BJU	No drugs detected utilizing screening methods.
PFV2P9	Oxycodone
PQVR9V	ELISA Oxycodone
PRMQLU	No drugs detected utilizing screening methods.
PVL2HU	No drugs detected utilizing screening methods.
Q9PRTZ	No drugs detected utilizing screening methods.
QEVNEL	Oxycodone Oxymorphone
QVZVUM	No drugs detected utilizing screening methods.
QYFH8T	oxycodone
R22LFQ	oxycodone
R4N7GN	No drugs detected utilizing screening methods.
R8P7J7	Oxycodone
RBCN2Q	oxycodone-opioids
RU3ZQB	Oxycodone, Noroxycodone, Oxymorphone
T3QENE	No drugs detected utilizing screening methods.
T3VRCB	opiates
T6HBD9	Noroxycodone, oxycodone, oxymorphone
T7U38A	Oxycodone
TF2K4M	Oxycodone
U82PEM	No drugs detected utilizing screening methods.
U9DG9P	Opiates (Oxyc 1&2 and Opds)
UCWGMK	No drugs detected utilizing screening methods.
UZHJHF	Oxycodone-metabolite probably Noroxycodone

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
V4XAKQ	Oxycodone
VBJ8AD	No drugs detected utilizing screening methods.
VR3ZXG	Oxycodone Oxymorphone
W68H9G	No drugs detected utilizing screening methods.
WZCR36	Oxycodone
XCZBUF	oxycodone oxymorphone
XE9KQJ	Oxycodone
XHQK4D	oxycodone, oxymorphone
XJZPJM	oxycodone
XPQZUL	Oxycodone
XZ7U6E	Oxycodone
YJEF4R	Oxycodone, Oxymorphone
ZA74PA	Benzoylcegonine Oxycodone Oxymorphone
ZFFKXX	Oxycodone

Screening Response Summary for Item 2	Participants: 110
Oxycodone:	69
Oxymorphone:	28
Noroxycodone:	10
Opioids:	11
Other Drugs Detected:	9
No Drugs Detected Utilizing Screening Methods:	35

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 2

TABLE 2B

Item Scenario:

A 26 year old male was arrested for attempted robbery of a local drug store. Upon arrest he displayed agitated behavior and was sweating profusely. Urine was collected within 4 hours of arrest.

Item Contents and Preparation Concentration: Oxycodone (200 ng/mL)
 Oxymorphone (100 ng/mL)
 Noroxycodone (400 ng/mL)

What drugs/metabolites were detected in Item 2?				
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty Units
2D7UBE	Oxycodone	✓		
	Oxymorphone	✓		
	Noroxycodone	✓		
33K6QZ	oxycodone	✓		
	oxymorphone	✓		
372DEY	Oxycodone	✓		
	Oxymorphone	✓		
3R2FBF	Oxycodone	✓		
3V4EL9	Oxycodone	✓		
	Oxymorphone	✓		
	Noroxycodone	✓		
46ZY6C	Oxycodone	✓		
	Oxycodone metabolite	✓		
47VKRB	Oxycodone	✓		
	Noroxycodone	✓		
4KGYVB	Oxycodone	✓		
	Oxymorphone	✓		
4M67KD	oxycodone	✓		
62FC4C	Oxycodone	✓		
	Noroxycodone	✓		
6XGXJ8	Oxycodone	✓		
	Oxymorphone	✓		
76EARA	oxycodone	✓		
7HMTQ4	Oxycodone	✓		
	Oxymorphone	✓		
7QHQGD	Oxycodone	✓		
	Oxymorphone	✓		
8A4698	Oxycodone	✓		
	Oxymorphone	✓		

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
8DL4L3	oxycodone		0.20		mg/l
	oxymorphone		0.15		mg/l
8JQ3YD	No drugs/metabolites detected utilizing confirmatory methods.				
8PFKB4	Oxycodone	✓			
	oxymorphone	✓			
8R8JP2	No drugs/metabolites detected utilizing confirmatory methods.				
8V7UL2	No drugs/metabolites detected utilizing confirmatory methods.				
9CNDTT	oxycodone	✓			
	oxymorphone	✓			
	Noroxycodone	✓			
9FBVBD	oxycodone	✓			
9J4WB8	Oxycodone	✓			
9YZBBZ	oxycodone	✓			
A3DB8R	Iranox	✓			
	Pinacol	✓			
	Tryptamine	✓			
ATNMB4	Oxycodone	✓			
	oxymorphone	✓			
	noroxycodone	✓			
B47LK7	oxycodone	✓			
BMJ7EN	No drugs/metabolites detected utilizing confirmatory methods.				
BRWNW7	oxycodone	✓			
	oxymorphone	✓			
CDAU3R	Oxycodone	✓			
	Noroxycodone	✓			
CW4WEL	Oxycodone	✓			
	Oxymorphone	✓			
	Noroxycodone	✓			
D7KVNN	Oxycodone	✓			
	Noroxycodone	✓			
D8XACX	Oxycodone	✓			
	Oxymorphone	✓			

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
DBYE76	oxycodone	✓			
DTH8U9	oxycodone	✓			
E4WNZK	Oxycodone	✓			
	Oxymorphone	✓			
	Noroxycodone	✓			
EMMZP6	Oxycodone	✓			
	Oxymorphone	✓			
	Noroxycodone	✓			
F2M227	Oxycodone	✓			
	Oxymorphone	✓			
FFKAJK	No drugs/metabolites detected utilizing confirmatory methods.				
FJ7R27	oxycodone	✓			
FXZJL	Tryptamine	✓			
GH8RAR	Oxycodone	✓			
	Oxymorphone	✓			
GLTTJY	Oxycodone	✓			
	Oxymorphone	✓			
HDTXUY	Oxycodone		170.63		ng/ml
	Oxymorphone		115.88		ng/ml
HPMAAX	oxycodone	✓			
	oxymorphone	✓			
	Noroxycodone	✓			
JHGTDH	Oxycodone	✓			
	Oxymorphone	✓			
KEEE4X	oxycodone	✓			
KVJLHZ	Oxycodone	✓			
LZ8RCT	Oxycodone	✓			
	oxymorphone	✓			
	noroxycodone	✓			
MKDKTK	Oxycodone	✓			
MNENMT	oxycodone	✓			
MYW6FZ	Oxycodone	✓			
	Oxymorphone	✓			
NFETXT	Oxycodone		202		ng/mL

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?				
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty Units
NH3ZMW	Oxycodone	✓		
	Oxymorphone	✓		
NHHJ8U	Oxycodone	✓		
PE2BJU	oxycodone	✓		
PQVR9V	Oxycodone	✓		
	Oxymorphone	✓		
	Noroxycodone	✓		
PRMQLU	oxycodone	✓		
PTZKZ9	Oxycodone	✓		
PVL2HU	oxycodone	✓		
QAZUGK	Oxycodone	✓		
	oxymorphone	✓		
	noroxycodone	✓		
QEVNEL	Oxycodone	✓		
	Oxymorphone	✓		
QJBV3K	Oxycodone	✓		
	oxymorphone	✓		
QYFH8T	oxycodone	✓		
R22LFQ	oxycodone	✓		
R4N7GN	Oxycodone	✓		
	Oxymorphone	✓		
	Noroxycodone	✓		
R8P7J7	Oxycodone	✓		
	Noroxycodone	✓		
RBCN2Q	oxycodone	✓		
RU3ZQB	Oxycodone	✓		
	Oxymorphone	✓		
	Noroxycodone	✓		
T3VRCB	oxycodone	✓		
	oxymorphone	✓		
T6HBD9	Oxycodone	✓		
	Oxymorphone	✓		
	Noroxycodone	✓		
T7U38A	Oxycodone	✓		
	Noroxycodone	✓		

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?				
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty Units
TF2K4M	Oxycodone	✓		
U9DG9P	Oxycodone	✓		
	Oxymorphone	✓		
UZHJHF	Oxycodone	✓		
V4XAKQ	Oxycodone	✓		
VR3ZXG	Oxycodone	✓		
	Oxymorphone	✓		
XCZBUF	oxycodone	✓		
	oxymorphone	✓		
XE9KQJ	Oxycodone	✓		
XHQK4D	oxycodone	✓		
XJZPJM	oxycodone	✓		
XPQZUL	Oxycodone	✓		
YJEF4R	Oxycodone	✓		
	Oxymorphone	✓		
ZA74PA	Oxycodone	✓		
	Oxymorphone	✓		

Confirmatory Response Summary for Item 2	Participants: 84
Oxycodone: 77	
Oxymorphone: 40	
Noroxycodone: 20	
Other Identified Drugs/Metabolites: 4	
No Drugs/Metabolites Detected Utilizing Confirmatory Methods: 5	

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 2

TABLE 2C

Item 2 Raw Data - Oxycodone
Preparation concentration: 200 ng/mL

WebCode	List of Raw Data determinations (ng/mL)			
HDTXUY	166.98	174.30		
NFETXT	209.00	218.00	197.00	183.00

Statistical Analysis for Item 2 - Oxycodone

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

TABLE 2C: Raw Data - Item 2
Item 2 Raw Data - Oxymorphone
Preparation concentration: 100 ng/mL

WebCode List of Raw Data determinations (ng/mL)

HDTXUY 118.41 113.40

Statistical Analysis for Item 2 - Oxymorphone

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

TABLE 2C: Raw Data - Item 2
Item 2 Raw Data - Noroxycodone
Preparation concentration: 400 ng/mL

WebCode List of Raw Data determinations (ng/mL)

No Raw Data results were reported for this Drug/Analyte for Item 2.

Statistical Analysis for Item 2 - Noroxycodone

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

Reporting Procedures - Item 2

TABLE 2D - Item 2

WebCode	Quantitative Reporting Procedures
---------	-----------------------------------

8DL4L3	A single determination.
HDTXUY	The mean of duplicate/several determinations.
NFETXT	The mean of duplicate/several determinations.

Response Summary for Item 2	Participants: 3
-----------------------------	-----------------

A single determination:	1 (33.3%)	
The mean of duplicate/several determinations:	2 (66.67%)	
Other:	0 (0.0%)	

Methods of Analysis - Item 2

TABLE 2E - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
29UQKC	Immunoassay GC/MS	✓ ✓		
2D7UBE	LC-QTOF-MS LC/MS/MS	✓	✓	
2G4FXB	Immunoassay GC/MS	✓ ✓		
33K6QZ	LC/MS/MS GC/MS	✓	✓	
372DEY	LC/MS/MS	✓	✓	
3AL8AE	Immunoassay	✓		
3DY877	Immunoassay	✓		
3R2FBF	Immunoassay LC/MS/MS	✓	✓	
3V4EL9	LC-QTOF-MS	✓	✓	
46ZY6C	GC/MS LC-QTOF Immunoassay	✓ ✓ ✓	✓	
47VKRB	Immunoassay LC-QTOF GC/MS LC/MS/MS	✓ ✓ ✓	✓ ✓	
4KGYVB	Immunoassay GC/MS GC/NPD LC/MS/MS	✓ ✓	✓ ✓	
4M67KD	LC/MS/MS GC/MS Immunoassay	✓	✓ ✓	
62FC4C	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
6XGXJ8	LC-QTOF-MS LC/MS/MS	✓	✓	
74HP6A	Immunoassay	✓		
76EARA	Immunoassay GC/MS	✓	✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
7HMTQ4	LC/MS LC/MS/MS	✓	✓	
7QHQGD	Immunoassay LC/MS/MS GC/MS LC-QExactive	✓ ✓	✓ ✓ ✓	
7RCGMR	GC/MS	✓		
7T6AHB	Immunoassay	✓		
8A4698	LC/MS/MS	✓	✓	
8DL4L3	LC/MS/MS			✓
8JQ3YD	Immunoassay GC/MS	✓	✓	
8MA3D8	Immunoassay GC/MS	✓ ✓		
8PFKB4	GC/MS	✓	✓	
8R8JP2	Immunoassay LC/MS/MS	✓	✓	✓
8V7UL2	Immunoassay LC/MS/MS	✓	✓	✓
9CNDTT	LC/MS/MS	✓	✓	
9FBVBD	GC/MS LC-HRMS/MS	✓ ✓	✓ ✓	
9J4WB8	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
9YZBBZ	Immunoassay GC/MS	✓	✓	
A2LEJX	Immunoassay GC/MS	✓ ✓		
A3DB8R	GC/MS	✓	✓	
AAWG6Y	Immunoassay GC/MS	✓ ✓		
ATNMB4	GC/MS		✓	
B47LK7	Immunoassay GC/MS LC/MS/MS	✓ ✓ ✓	✓ ✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
BMJ7EN	Immunoassay GC/MS	✓	✓	
BRWNW7	Immunoassay GC/MS	✓	✓	
C2GEW3	Immunoassay GC/MS	✓ ✓		
C6GQR3	Immunoassay GC/MS	✓ ✓		
CDAU3R	Immunoassay LC-QTOF-MS GC/MS	✓ ✓	✓	
CW4WEL	LC-QTOF-MS	✓	✓	
D4H3NX	Immunoassay GC/MS	✓ ✓		
D7KVNN	LC-QTOF		✓	
D8XACX	LC/MS/MS GC/MS Rapid Chromatographic Immunoassay	✓ ✓ ✓	✓ ✓	
DBYE76	LC-HRMS/MS	✓	✓	
DTH8U9	LC-HRMS/MS GC/MS	✓	✓ ✓	
E4WNZK	Immunoassay LC-QTOF GC/MS LC-QTOF	✓ ✓	✓ ✓	
EMMZP6	Immunoassay GC/MS	✓ ✓	✓	
F2M227	Immunoassay LC/MS/MS	✓	✓	
FDTEUR	Immunoassay GC/MS	✓ ✓		
FFKAJK	LC/MS/MS	✓	✓	✓
FJ7R27	LC-HRMS/MS GC/MS	✓	✓	
FJKHMV	Immunoassay GC/MS	✓ ✓		
FXZJL	GC/MS	✓		

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
GH8RAR	LC-QTOF	✓		
	LC/MS/MS		✓	
GLTTJY	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
HDTXUY	LC/MS/MS	✓	✓	✓
HPMAAX	GC/MS	✓		
	LC-QTOF-MS		✓	
	LC/MS/MS	✓	✓	
JFTLPF	Immunoassay	✓		
JHGTDH	Immunoassay	✓		
	GC/MS		✓	
KEEE4X	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
KN3AZT	Immunoassay	✓		
	GC/MS	✓		
KVJLHZ	Immunoassay	✓		
	GC/MS		✓	
LLPZML	Immunoassay	✓		
	GC/MS	✓		
LNGVCF	Immunoassay	✓		
LZ8RCT	GC/MS		✓	
MKDKTK	Immunoassay	✓		
	GC/MS		✓	
MNENMT	GC/MS	✓	✓	
	LC/MS/MS	✓		
MYW6FZ	Immunoassay	✓		
	LC/MS/MS		✓	
NFETXT	Immunoassay	✓		
	LC-QTOF		✓	
	LC/MS/MS		✓	✓
NH3ZMW	Immunoassay	✓		
	LC/MS/MS		✓	
NHHJ8U	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
NP3JKL	Immunoassay	✓		
PBFT2A	Immunoassay	✓		
PE2BJU	Immunoassay GC/MS LC/MS/MS	✓		✓ ✓
PFV2P9	Immunoassay	✓		
PQVR9V	Immunoassay GC/MS	✓ ✓		✓
PRMQLU	Immunoassay LC/MS/MS GC/MS	✓		✓ ✓
PTZKZ9	GC/MS			✓
PVL2HU	Immunoassay GC/MS LC/MS/MS	✓		✓ ✓
Q9PRTZ	Immunoassay	✓		
QAZUGK	GC/MS			✓
QEVNEL	LC-QTOF-MS LC/MS/MS	✓		✓
QJBV3K	GC/MS			✓
QVZVUM	Immunoassay GC/MS	✓ ✓		
QYFH8T	LC/MS/MS GC/MS Immunoassay	✓ ✓ ✓		✓ ✓
R22LFQ	Immunoassay LC/MS/MS GC/MS	✓ ✓ ✓		✓ ✓
R4N7GN	Immunoassay LC-QTOF-MS GC/MS	✓		✓ ✓
R8P7J7	ELISA LC/MS/MS	✓		✓
RBCN2Q	Immunoassay LC/MS/MS GC/MS	✓ ✓ ✓		✓ ✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
RU3ZQB	Immunoassay LC-QTOF-MS GC/MS	✓ ✓	✓	
T3QENE	Immunoassay GC/MS	✓ ✓		
T3VRCB	Immunoassay GC/MS	✓	✓	
T6HBD9	LC/MS/MS	✓	✓	
T7U38A	Immunoassay GC/MS	✓	✓	
TF2K4M	Immunoassay LC/MS/MS GC/MS	✓ ✓ ✓	✓ ✓	
U82PEM	Immunoassay	✓		
U9DG9P	Immunoassay LC/MS/MS	✓	✓	
UZHJHF	LC/MS	✓	✓	
V4XAKQ	LC-HRMS/MS	✓	✓	
VBJ8AD	Immunoassay GC/MS	✓ ✓		
VR3ZXG	LC-QTOF-MS LC/MS/MS	✓	✓	
W68H9G	Immunoassay GC/MS	✓ ✓		
WZCR36	Immunoassay	✓		
XCZBUF	Immunoassay GC/MS LC/MS/MS	✓ ✓	✓	
XE9KQJ	Immunoassay LC/MS/MS GC/MS	✓ ✓	✓ ✓ ✓	
XHQK4D	LC/MS/MS GC/MS	✓	✓	
XJZPJM	hrams GC/MS	✓	✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
XPQZUL	Immunoassay	✓		
	LC/MS		✓	
	GC/MS		✓	
XZ7U6E	Immunoassay	✓		
YJEF4R	LC/MS/MS	✓	✓	
ZA74PA	LC/MS/MS	✓	✓	
ZFFKXX	Immunoassay	✓		

Response Summary for Item 2 - Methods of Analysis		Participants: 115		
		Screening	Confirmatory	Quantitation
Immunoassay:		75	1	0
GC/MS:		35	50	0
LC/MS:		2	2	0
LC/MS/MS:		22	44	6
Other:		21	13	0

Additional Comments for Item 2

TABLE 2F

WebCode	Item Comments
29UQKC	Drug screen: screening/confirmation - Promazine - internal standard
2G4FXB	Promazine (ISTD) - Drug Screen for Urine
3AL8AE	Oxycodone cutoff is 100 ng/mL. Creatinine normal
3R2FBF	The cut-off value of Oxycodone is 50 ng/mL for LC/MS/MS
3V4EL9	Estazolam was used as internal standard. Noroxycodone was identified by LC-MS-MS library searches since the laboratory does not have reference material
4M67KD	Internal standard - mepivacaine. Oxycodone Limit of detection=6.2 micrograms/liter
6XGXJ8	Oxycodone LOD set at 200 ng/mL. Oxymorphone LOD set at 300 ng/mL
74HP6A	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP.
7QHQGD	Noroxycodone detected, but not reported by our laboratory.
7RCGMR	Liquid-liquid extraction (H+/OH-) with DCM followed by derivatisation with BSTFA
7T6AHB	Oxycodone assay cutoff: 100ng/mL. Creatinine normal
8JQ3YD	At present the following compounds are not included in the GCMS confirmatory testing method: Oxycodone, Oxymorphone, Hydrocodone, & Hydromorphone.
8MA3D8	Promazine was used as an internal standard.
8R8JP2	Basic Drug screen ran as a result of Amphetamine presumptive positive came back not detected. The laboratory does not have a confirmation method to confirm the presumptive positive oxycodone/oxymorphone result. The item was analyzed for the following drugs utilizing the listed methods: Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem. Basic Drug Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: amphetamine, diphenhydramine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, LSD. Qualitatively: ephedrine/pseudoephedrine, psilocin
8V7UL2	This sample screened presumptive positive for benzoylecgonine and oxycodone/oxymorphone, however our laboratory is not currently able to confirm these compounds. Therefore, confirmatory testing for benzoylecgonine and oxycodone/oxymorphone was not performed. This sample screened presumptive positive for amphetamine and confirmatory testing was performed, however this analyte was not detected. The limit of quantitation for amphetamine is 5 ng/mL.
9CNDTT	screening performed 4/3/24, confirmatory testing on 4/5/24
9FBVBD	Internal standard - Mepivacaine. Artifacts - caffeine. Metabolite - noroxycodone
9J4WB8	The Internal standard was used is Codeine D3
9YZBBZ	Confirmatory ISTD: NPA and SKF. our current GC/MS method does not extract oxymorphone and our LC/MS-MS method that is used for oxycodone/oxymorphone is only validated for blood.
ATNMB4	Internal standard: Flurazepam . Sample preparation: L/L extraction . The final extract is derivatized with BSTFA and analyzed by GC/MS
B47LK7	Internal Standard GC/MS & LC/MS/MS: mepivacaine
BMJ7EN	Confirmatory cutoff for our lab is 300 ng/mL

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
CDAU3R	Mepivacaine - Internal standard for QTOF and GCMS.
CW4WEL	IS: Triazolam-D4; LOD: 10 ng/mL.
D8XACX	iCassette (THC) test device was used to screen for THC, referred to in 2-5 as rapid Chromatographic immunoassay.
DBYE76	IS: mepivacaine, mephobarbital
DTH8U9	LC-HRMS/MS internal standards: mepivacaine, mephobarbital. GC/MS internal standard: mepivacaine
EMMZP6	Hexobarbital, n-Propylamphetamine, and Mepivacaine were used as GC/MS internal standards.
FFKAJK	Panel includes only the following analytes: Cyclobenzaprine, Imipramine, Mitragnine, Zolpidem, Phencyclidine
FXZJL	- The sample contains methanol detected by GCMS-Hs. - Cyanophenol, Irganox & hydroquinone's were detected in the sample
HPMAAX	GC/MS was the screening method for the oxycodone and noroxycodone. LC-QTOF-MS was a confirmatory method for the oxycodone and noroxycodone. LC-MS/MS was also a confirmatory method for the oxycodone. LC-MS/MS was the screening and confirmatory method for the oxymorphone.
KEEE4X	Internal Standard: Mepivacaine
KN3AZT	Internal Standards used: Promazine.
KVJLHZ	LOD for oxy/opiates is 300ng/mL on ELISA
LNGVCF	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
MKDGTK	Internal Standard: Hydromorphone-D6. Limit of Detection: 50 ng/mL
NHHJ8U	Internal Standard: Mepivacaine
NP3JKL	This screened presumptive positive for amphetamine and oxycodone/oxymorphone. However, I am not qualified to confirm the presence of amphetamine, and our lab does not have the capabilities to confirm the presence of oxycodone/oxymorphone. The immunoassay tests for the following drugs: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylcegonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem
PE2BJU	Mepivacaine was the internal standard used for GC/MS and LC/MS/MS methods.
PFV2P9	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
PQVR9V	N-Propylamphetamine, Mepivacaine, and Hexobarbital were used as Internal Standards.
PRMQLU	mepivacaine used as internal standard
PTZKZ9	Internal Standard: SKF-525A
PVL2HU	mepivacaine internal standard used for gcms and lcmsms analysis
QAZUGK	Internal standard: Flurazepam
QEVNEL	Oxycodone LOD set at 200 ng/mL. Oxymorphone LOD set at 300 ng/mL

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
QJBV3K	Tetracosane is the internal standard
QVZVUM	Internal standard used for drug screen was promazine.
QYFH8T	Internal Standard - mepivacaine
R22LFQ	Internal Standard: mepivacaine
RBCN2Q	Internal Standard-Mepivacaine/Nalorphine, Mepivacaine
RU3ZQB	Internal standard was Mepivacaine.
T7U38A	Oxymorphone was observed in the sample, but did not meet acceptance criteria for identification.
TF2K4M	internal standard=mepivacaine
V4XAKQ	Mepivacaine and Mephobarbital internal standards used.
VR3ZXG	Oxycodone LOD set at 200 ng/mL. Oxymorphone LOD set at 300 ng/mL
W68H9G	Promazine used as internal standard for GC/MS screening analysis.
WZCR36	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
XCZBUF	GC/MS ITSD - phenyltoloxamine LC/MS-MS ISTD - d3-Hydromorphone d3-Oxycodone
XE9KQJ	internal standard: mepivacaine
XHQK4D	oxymorphone not confirmed as it is not detectable in our current GCMS confirmatory method.
XJZPJM	HRAMS i.s. mepivacaine. GCMS i.s. mepivacaine
XPQZUL	Internal Standard: Mepivacaine
XZ7U6E	Chemiluminescence Immunoassay screening technique
YJEF4R	Oxycodone LOD 5ng/ml; ISTD Oxycodone-d6 Oxymorphone LOD 5ng/ml; ISTD Oxymorphone-d3
ZA74PA	Oxycodone: ISTD Oxycodone-d6; LOD 5ng/mL. Oxymorphone: ISTD Oxymorphone-d3; LOD 5ng/mL
ZFFKXX	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.

Screening Results - Item 3

TABLE 3A

Item Scenario:

A 22 year old female visited the police station after suspecting she was the victim of a drug-facilitated sexual assault. She was at a party the night before where she encountered a male who provided her with at least two alcoholic beverages. The victim described her symptoms as: feeling unusual, unable to focus or keep her eyes open, difficulty speaking, body incoordination, drowsiness, and memory loss. A urine sample was collected within 72 hours.

Item Contents and Preparation Concentration: Diphenhydramine (50 ng/mL)

WebCode	Screening Results
29UQKC	Diphenhydramine
2G4FXB	Diphenhydramine
33K6QZ	diphenhydramine
372DEY	Diphenhydramine
3AL8AE	No drugs detected utilizing screening methods.
3DY877	Amphetamine
3R2FBF	No drugs detected utilizing screening methods.
3V4EL9	Diphenhydramine
46ZY6C	Diphenhydramine
4KGYVB	Diphenhydramine
4M67KD	No drugs detected utilizing screening methods.
62FC4C	No drugs detected utilizing screening methods.
6XGXJ8	Buprenorphine
74HP6A	No drugs detected utilizing screening methods.
76EARA	No drugs detected utilizing screening methods.
7HMTQ4	Diphenhydramine
7QHQQD	Diphenhydramine
7RCGMR	Diphenhydramine, methcatinone
7T6AHB	No drugs detected utilizing screening methods.
8A4698	No drugs detected utilizing screening methods.
8DL4L3	Diphenhydramine
8JQ3YD	Diphenhydramine
8MA3D8	Diphenhydramine
8PFKB4	No drugs detected utilizing screening methods.

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
8R8JP2	Amphetamine
8V7UL2	Benzoylcegonine, Amphetamine
9CNDTT	diphenhydramine
9FBVBD	diphenhydramine
9J4WB8	No drugs detected utilizing screening methods.
9YZBBZ	amphetamine
A2LEJX	Diphenhydramine
A3DB8R	No drugs detected utilizing screening methods.
AAWG6Y	Diphenhydramine
B47LK7	diphenhydramine
BMJ7EN	No drugs detected utilizing screening methods.
BRWNW7	No drugs detected utilizing screening methods.
C2GEW3	Diphenhydramine
C6GQR3	Diphenhydramine
CDAU3R	Diphenhydramine
CW4WEL	Diphenhydramine
D4H3NX	Diphenhydramine
D8XACX	Diphenhydramine/Dimenhydrinate
DBYE76	diphenhydramine
DTH8U9	diphenhydramine
E4WNZK	No drugs detected utilizing screening methods.
EMMZP6	Diphenhydramine (GC/MS)
F2M227	No drugs detected utilizing screening methods.
FDTEUR	Diphenhydramine
FFKAJK	No drugs detected utilizing screening methods.
FJ7R27	diphenhydramine
FJKHMV	Diphenhydramine
FXZJL	No drugs detected utilizing screening methods.

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
GH8RAR	Diphenhydramine
GLTTJY	No drugs detected utilizing screening methods.
HDTXUY	Diphenhydramine
HPMAAX	diphenhydramine
JFTLPF	No drugs detected utilizing screening methods.
JHGTDH	No drugs detected utilizing screening methods.
KEEE4X	diphenhydramine
KN3AZT	No drugs detected utilizing screening methods.
KVJLHZ	No drugs detected utilizing screening methods.
LLPZML	Diphenhydramine
LNGVCF	No drugs detected utilizing screening methods.
MKDKTK	Antihistamines
MNENMT	No drugs detected utilizing screening methods.
MYW6FZ	No drugs detected utilizing screening methods.
NFETXT	No drugs detected utilizing screening methods.
NH3ZMW	No drugs detected utilizing screening methods.
NHHJ8U	Diphenhydramine
NP3JKL	Amphetamine
PBFT2A	No drugs detected utilizing screening methods.
PE2BJU	No drugs detected utilizing screening methods.
PFV2P9	No drugs detected utilizing screening methods.
PQVR9V	Diphenhydramine via GC/MS
PRMQLU	No drugs detected utilizing screening methods.
PVL2HU	No drugs detected utilizing screening methods.
Q9PRTZ	No drugs detected utilizing screening methods.
QEVNEL	No drugs detected utilizing screening methods.
QVZVUM	Diphenhydramine
QYFH8T	diphenhydramine

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
R22LFQ	diphenhydramine
R4N7GN	No drugs detected utilizing screening methods.
R8P7J7	No drugs detected utilizing screening methods.
RBCN2Q	Diphenhydramine
RU3ZQB	Diphenhydramine
T3QENE	Diphenhydramine
T3VRCB	No drugs detected utilizing screening methods.
T6HBD9	Diphenhydramine
T7U38A	No drugs detected utilizing screening methods.
TF2K4M	Diphenhydramine
U82PEM	No drugs detected utilizing screening methods.
U9DG9P	No drugs detected utilizing screening methods.
UCWGMK	diphenhydramine
UZHJHF	No drugs detected utilizing screening methods.
V4XAKQ	Diphenhydramine
VBJ8AD	Diphenhydramine
VR3ZXG	No drugs detected utilizing screening methods.
W68H9G	Diphenhydramine
WZCR36	No drugs detected utilizing screening methods.
XCZBUF	No drugs detected utilizing screening methods.
XE9KQJ	Diphenhydramine
XHQK4D	No drugs detected utilizing screening methods.
XJZPJM	diphenhydramine
XPQZUL	Diphenhydramine
XZ7U6E	No drugs detected utilizing screening methods.
YJEF4R	Diphenhydramine
ZA74PA	Benzoyllecgonine Diphenhydramine
ZFFKXX	No drugs detected utilizing screening methods.

Screening Response Summary for Item 3		Participants: 108
Diphenhydramine:	54	
Other Drugs Detected:	10	
No Drugs Detected Utilizing Screening Methods:	47	

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 3

TABLE 3B

Item Scenario:

A 22 year old female visited the police station after suspecting she was the victim of a drug-facilitated sexual assault. She was at a party the night before where she encountered a male who provided her with at least two alcoholic beverages. The victim described her symptoms as: feeling unusual, unable to focus or keep her eyes open, difficulty speaking, body incoordination, drowsiness, and memory loss. A urine sample was collected within 72 hours.

Item Contents and Preparation Concentration: Diphenhydramine (50 ng/mL)

What drugs/metabolites were detected in Item 3?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
29UQKC	Diphenhydramine	✓			
2G4FXB	Diphenhydramine	✓			
33K6QZ	diphenhydramine	✓			
372DEY	Diphenhydramine	✓			
3R2FBF	Diphenhydramine	✓			
3V4EL9	Diphenhydramine	✓			
46ZY6C	Diphenhydramine	✓			
4KGYVB	Diphenhydramine	✓			
4M67KD	diphenhydramine	✓			
62FC4C	Diphenhydramine	✓			
6XGXJ8	No drugs/metabolites detected utilizing confirmatory methods.				
76EARA	No drugs/metabolites detected utilizing confirmatory methods.				
7HMTQ4	Diphenhydramine	✓			
7QHQGD	Diphenhydramine	✓			
8DL4L3	Diphenhydramine		0.046		mg/l
8JQ3YD	Diphenhydramine	✓			
8MA3D8	Diphenhydramine	✓			
8PFKB4	No drugs/metabolites detected utilizing confirmatory methods.				
8R8JP2	Diphenhydramine		65	25	ng/mL
8V7UL2	Diphenhydramine		56	21	ng/mL
9CNDTT	diphenhydramine	✓			
9FBVBD	diphenhydramine	✓			
9J4WB8	Diphenhydramine	✓			

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
9YZBBZ	Diphenhydramine	✓			
A2LEJX	Diphenhydramine	✓			
A3DB8R	Tryptamine	✓			
AAWG6Y	Diphenhydramine	✓			
ATNMB4	No drugs/metabolites detected utilizing confirmatory methods.				
B47LK7	diphenhydramine	✓			
BRWNW7	No drugs/metabolites detected utilizing confirmatory methods.				
C2GEW3	Diphenhydramine	✓			
C6GQR3	Diphenhydramine	✓			
CDAU3R	Diphenhydramine	✓			
CW4WEL	Diphenhydramine	✓			
D4H3NX	Diphenhydramine	✓			
D7KVNN	Diphenhydramine	✓			
D8XACX	Diphenhydramine/Dimenhydrinate	✓			
DBYE76	diphenhydramine	✓			
DTH8U9	diphenhydramine	✓			
EMMZP6	Diphenhydramine				
F2M227	No drugs/metabolites detected utilizing confirmatory methods.				
FDTEUR	Diphenhydramine	✓			
FFKAJK	No drugs/metabolites detected utilizing confirmatory methods.				
FJ7R27	diphenhydramine	✓			
FJKHMV	Diphenhydramine	✓			
FXZJLL	Tryptamine , Caffeine, Carvacol	✓			
GH8RAR	Diphenhydramine	✓			
GLTTJY	Diphenhydramine	✓			
HDTXUY	Diphenhydramine	✓			
HPMAAX	diphenhydramine	✓			

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?				
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty Units
JHGTDH	No drugs/metabolites detected utilizing confirmatory methods.			
KEEE4X	diphenhydramine	✓		
KVJLHZ	No drugs/metabolites detected utilizing confirmatory methods.			
LLPZML	Diphenhydramine	✓		
LZ8RCT	No drugs/metabolites detected utilizing confirmatory methods.			
MKDKTK	Diphenhydramine	✓		
NFETXT	No drugs/metabolites detected utilizing confirmatory methods.			
NH3ZMW	No drugs/metabolites detected utilizing confirmatory methods.			
NHHJ8U	Diphenhydramine	✓		
PE2BJU	diphenhydramine	✓		
PQVR9V	Diphenhydramine	✓		
PRMQLU	diphenhydramine	✓		
PTZKZ9	Diphenhydramine	✓		
PVL2HU	diphenhydramine	✓		
QAZUGK	No drugs/metabolites detected utilizing confirmatory methods.			
QJBV3K	No drugs/metabolites detected utilizing confirmatory methods.			
QVZVUM	Diphenhydramine	✓		
QYFH8T	diphenhydramine	✓		
R22LFQ	diphenhydramine	✓		
R4N7GN	No drugs/metabolites detected utilizing confirmatory methods.			
RBCN2Q	Diphenhydramine	✓		
RU3ZQB	Diphenhydramine	✓		
T3QENE	Diphenhydramine	✓		
T6HBD9	Diphenhydramine	✓		
T7U38A	diphenhydramine	✓		
TF2K4M	diphenhydramine	✓		

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?				
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty Units
UCWGMK	diphenhydramine	✓		
UZHJHF	No drugs/metabolites detected utilizing confirmatory methods.			
V4XAKQ	Diphenhydramine	✓		
VBJ8AD	Diphenhydramine	✓		
W68H9G	Diphenhydramine	✓		
XE9KQJ	Diphenhydramine	✓		
XJZPJM	diphenhydramine	✓		
XPQZUL	Diphenhydramine	✓		
YJEF4R	Diphenhydramine	✓		
ZA74PA	Diphenhydramine	✓		

Confirmatory Response Summary for Item 3	Participants: 86
Diphenhydramine: 68	
Other Identified Drugs/Metabolites: 2	
No Drugs/Metabolites Detected Utilizing Confirmatory Methods: 16	

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 3

TABLE 3C

Item 3 Raw Data - Diphenhydramine Preparation concentration: 50 ng/mL

WebCode	List of Raw Data determinations (ng/mL)	
8R8JP2	65.000	66.000
8V7UL2	56.940	58.710

Statistical Analysis for Item 3 - Diphenhydramine

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

Reporting Procedures - Item 3

TABLE 3D - Item 3

WebCode	Quantitative Reporting Procedures
---------	-----------------------------------

8DL4L3	A single determination.
8R8JP2	Lowest of duplicate samples, truncated
8V7UL2	The lowest of duplicates

Response Summary for Item 3	Participants: 3
-----------------------------	-----------------

A single determination:	1 (33.3%)
The mean of duplicate/several determinations:	0 (0.00%)
Other:	2 (66.7%)

Methods of Analysis - Item 3

TABLE 3E - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
29UQKC	Immunoassay GC/MS	✓ ✓	✓	
2G4FXB	Immunoassay GC/MS	✓ ✓	✓	
33K6QZ	LC/MS/MS GC/MS	✓	✓	
372DEY	LC/MS/MS	✓	✓	
3AL8AE	Immunoassay	✓		
3DY877	Immunoassay	✓		
3R2FBF	Immunoassay LC/MS/MS	✓	✓	
3V4EL9	LC-QTOF-MS	✓	✓	
46ZY6C	GC/MS LC-QTOF Immunoassay	✓ ✓ ✓	✓	
4KGYVB	Immunoassay GC/NPD GC/MS LC/MS/MS	✓ ✓	✓ ✓	
4M67KD	LC/MS/MS GC/MS Immunoassay	✓	✓ ✓	
62FC4C	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
6XGXJ8	LC-QTOF-MS	✓		
74HP6A	Immunoassay GC/MS	✓ ✓		
76EARA	Immunoassay GC/MS	✓	✓	
7HMTQ4	LC/MS LC/MS/MS	✓	✓	
7QHQQD	Immunoassay LC/MS/MS GC/MS	✓ ✓	✓ ✓	
7RCGMR	GC/MS	✓		

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
7T6AHB	Immunoassay	✓		
8A4698	LC/MS/MS	✓		
8DL4L3	LC/MS/MS			✓
8JQ3YD	GC/MS	✓	✓	
8MA3D8	Immunoassay GC/MS	✓ ✓	✓	
8PFKB4	GC/MS	✓	✓	
8R8JP2	Immunoassay LC/MS/MS	✓	✓	✓
8V7UL2	Immunoassay LC/MS/MS	✓	✓	✓
9CNDTT	LC/MS/MS	✓	✓	
9FBVBD	GC/MS LC-HRMS/MS	✓ ✓	✓ ✓	
9J4WB8	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
9YZBBZ	Immunoassay GC/MS	✓	✓	
A2LEJX	GC/MS Immunoassay	✓ ✓	✓	
A3DB8R	GC/MS	✓	✓	
AAWG6Y	Immunoassay GC/MS	✓ ✓	✓	
ATNMB4	GC/MS		✓	
B47LK7	Immunoassay GC/MS LC/MS/MS	✓ ✓ ✓	✓ ✓	
BMJ7EN	Immunoassay	✓		
BRWNW7	Immunoassay LC/MS/MS GC/MS	✓	✓ ✓	
C2GEW3	Immunoassay GC/MS	✓ ✓	✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
C6GQR3	Immunoassay GC/MS	✓ ✓	✓	
CDAU3R	Immunoassay LC-QTOF-MS GC/MS	✓ ✓	✓	
CW4WEL	LC-QTOF-MS	✓	✓	
D4H3NX	Immunoassay GC/MS	✓ ✓	✓	
D7KVNN	GC/MS LC-QTOF		✓ ✓	
D8XACX	LC/MS/MS GC/MS Rapid Chromatographic Immunoassay	✓ ✓	✓	
DBYE76	LC-HRMS/MS	✓	✓	
DTH8U9	LC-HRMS/MS GC/MS	✓	✓ ✓	
E4WNZK	Immunoassay LC-QTOF	✓ ✓		
EMMZP6	Immunoassay GC/MS	✓ ✓	✓	
F2M227	Immunoassay	✓		
FDTEUR	Immunoassay GC/MS	✓ ✓	✓	
FFKAJK	LC/MS/MS	✓	✓	✓
FJ7R27	LC-HRMS/MS GC/MS	✓	✓	
FJKHMV	Immunoassay GC/MS	✓ ✓	✓	
GH8RAR	LC-QTOF LC/MS/MS	✓	✓	
GLTTJY	Immunoassay LC/MS/MS GC/MS	✓	✓ ✓	
HDTXUY	LC/MS/MS	✓	✓	
HPMAAX	LC-QTOF-MS LC/MS/MS	✓	✓	
JFTLPF	Immunoassay	✓		

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
JHGTDH	Immunoassay	✓	✓	
KEEE4X	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
KN3AZT	Immunoassay	✓		
	GC/MS	✓		
KVJLHZ	Immunoassay	✓		
	GC/MS		✓	
LLPZML	Immunoassay	✓		
	GC/MS	✓	✓	
LNGVCF	Immunoassay	✓		
LZ8RCT	GC/MS		✓	
MKDKTK	Immunoassay	✓		
	GC/MS		✓	
MNENMT	GC/MS	✓		
	LC/MS/MS	✓		
MYW6FZ	Immunoassay	✓		
NFETXT	Immunoassay	✓		
	LC-QTOF		✓	
	LC/MS/MS		✓	
NH3ZMW	Immunoassay	✓		
	LC/MS/MS		✓	
NHHJ8U	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
NP3JKL	Immunoassay	✓		
PBFT2A	Immunoassay	✓		
PE2BJU	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
PFV2P9	Immunoassay	✓		
PQVR9V	Immunoassay	✓		
	GC/MS	✓	✓	
PRMQLU	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
PTZKZ9	GC/MS		✓	
PVL2HU	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
Q9PRTZ	Immunoassay	✓		
QAZUGK	GC/MS		✓	
QEVNEL	LC-QTOF-MS	✓		
QJBV3K	GC/MS		✓	
QVZVUM	Immunoassay	✓		
	GC/MS	✓	✓	
QYFH8T	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
	Immunoassay	✓		
R22LFQ	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
R4N7GN	Immunoassay	✓		
	LC-QTOF-MS		✓	
	GC/MS		✓	
RBCN2Q	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
RU3ZQB	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
T3QENE	Immunoassay	✓		
	GC/MS	✓	✓	
T3VRCB	Immunoassay	✓		
T6HBD9	LC/MS/MS	✓	✓	
T7U38A	Immunoassay	✓		
	GC/MS		✓	
TF2K4M	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS	✓	✓	
U82PEM	Immunoassay	✓		
U9DG9P	Immunoassay	✓		

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
UCWGMK	LC/MS/MS GC/MS	✓	✓	
UZHJHF	LC/MS	✓	✓	
V4XAKQ	LC-HRMS/MS	✓	✓	
VBJ8AD	Immunoassay GC/MS	✓ ✓	✓	
VR3ZXG	LC-QTOF-MS	✓		
W68H9G	Immunoassay GC/MS	✓ ✓	✓	
WZCR36	Immunoassay	✓		
XCZBUF	Immunoassay GC/MS LC/MS/MS	✓ ✓ ✓		
XE9KQJ	Immunoassay LC/MS/MS GC/MS	✓ ✓	✓ ✓ ✓	
XHQK4D	LC/MS/MS	✓		
XJZPJM	hrams GC/MS	✓	✓	
XPQZUL	Immunoassay LC/MS GC/MS	✓	✓ ✓	
XZ7U6E	Immunoassay	✓		
YJEF4R	LC/MS/MS	✓	✓	
ZA74PA	LC/MS/MS	✓	✓	
ZFFKXX	Immunoassay	✓		

Response Summary for Item 3 - Methods of Analysis		Participants: 112		
	Screening	Confirmatory	Quantitation	
Immunoassay:	73	2	0	
GC/MS:	34	60	0	
LC/MS:	2	2	0	
LC/MS/MS:	23	33	4	
Other:	19	10	0	

Additional Comments for Item 3

TABLE 3F

WebCode	Item Comments
29UQKC	Drug screen: screening/confirmation - Promazine - internal standard. Benzodiazepine confirmation: Prazepam - internal standard. GHB screening: GHB-d6 - internal standard
2G4FXB	Promazine (ISTD) - Drug Screen for Urine. Prazepam (ISTD) - Benzodiazepine Confirmation in Urine. GHB-D6 (ISTD) - GHB Confirmation in Urine
3AL8AE	Creatinine normal
3R2FBF	The cut-off value of diphenhydramine is 25 ng/mL for LC/MS/MS
3V4EL9	Estazolam was used as internal standard
4M67KD	Internal Standard - mepivacaine. Diphenhydramine Limit of Detection - 10 micrograms/liter
6XGXJ8	Buprenorphine LOD set at 25 ng/mL
74HP6A	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP. Sexual assault cases are also screened for Ketamine, Gamma-hydroxybutyric acid (GHB), and Rohypnol using a GC/MS.
7RCGMR	Liquid-liquid extraction (H+/OH-) with DCM followed by derivatisation with BSTFA
7T6AHB	Creatinine normal
8MA3D8	Promazine was used as an internal standard for the Drug Screen analysis, prazepam was used as an internal standard for the Benzodiazepine confirmation analysis, and GHB-d6 was used as an internal standard for the GHB confirmation analysis.
8R8JP2	The item was analyzed for the following drugs utilizing the listed methods: Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem Basic Drug Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: amphetamine, diphenhydramine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, LSD. Qualitatively: ephedrine/pseudoephedrine, psilocin
8V7UL2	This sample screened presumptive positive for benzoylecgonine, however our laboratory is not currently able to confirm this compound. Therefore, confirmatory testing for benzoylecgonine was not performed. This sample screened presumptive positive for amphetamine and confirmatory testing was performed, however this analyte was not detected. The limit of quantitation for amphetamine is 5 ng/mL.
9CNDTT	screening performed 4/3/24, confirmatory testing on 4/5/24. GHB screening was also completed using single point LC/MS/MS on 4/8/24
9FBVBD	Internal standard - Mepivacaine. Artifacts - caffeine
9J4WB8	The Internal standard was used is Codeine D3
9YZBBZ	Confirmatory ISTD: NPA and SKF
ATNMB4	Internal standard: Flurazepam. Sample preparation: L/L extraction. The final extract is derivatized with BSTFA and analyzed by GC/MS
B47LK7	Internal Standard for GC/MS & LC/MS/MS: mepivacaine
CDAU3R	Mepivacaine - Internal standard for QTOF and GCMS.
CW4WEL	IS: Triazolam-D4; LOD: 10 ng/mL.

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
D8XACX	iCassette (THC) test device was used to screen for THC, referred to in 3-5 as rapid Chromatographic immunoassay.
DBYE76	IS: mepivacaine, mephobarbital
DTH8U9	LC-HRMS/MS internal standards: mepivacaine, mephobarbital. GC/MS internal standard: mepivacaine
EMMZP6	Hexobarbital, n-Propylamphetamine, and Mepivacaine were used as GC/MS internal standards. Lab does not offer DFC testing as part of scope.
FFKAJK	Panel includes only the following analytes: Cyclobenzaprine, Imipramine, Mitragynine, Zolpidem, Phencyclidine
HDTXUY	Quantitative analysis not performed due to lack of reference material.
KEEE4X	Internal Standard: Mepivacaine
KN3AZT	Internal Standards used: Promazine, Prazepam, GHB-D6.
KVJLHZ	No scheduled substances found. We do not typically report noncontrolled substances.
LNGVCF	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
MKDKTK	Internal Standard: Carbinoxamine. Limit of Detection: 20 ng/mL
NFETXT	Caffeine was detected in trace amount using targeted analysis on LCMSMS
NHHJ8U	Internal Standard: Mepivacaine
NP3JKL	This screened presumptive positive for amphetamine. However, I am not qualified to confirm the presence of this substance. The immunoassay tests for the following drugs: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem
PE2BJU	Mepivacaine was the internal standard used for GC/MS and LC/MS/MS methods.
PFV2P9	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
PQVR9V	N-Propylamphetamine, Mepivacaine, and Hexobarbital were used as Internal Standards. This lab does not offer DFC testing.
PRMQLU	mepivacaine used as internal standard
PTZKZ9	Internal Standard: SKF-525A
PVL2HU	mepivacaine internal standard used for gcms and lcmsms analysis
QAZUGK	Internal standard: Flurazepam
QJBV3K	Tetracosane is the internal standard
QVZVUM	Additional testing was performed for Lorazepam and GHB following the laboratory CSA testing approach. Internal standards used were Promazine (drug screen), Prazepam (benzodiazepine), and GHB D6 (GHB).
QYFH8T	Internal Standard - mepivacaine
R22LFQ	Internal Standard: mepivacaine

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
RBCN2Q	Internal Standard-Mepivacaine/Nalorphine, Mepivacaine
RU3ZQB	Internal Standard is Mepivacaine.
T6HBD9	GHB testing was not done as we only test for GHB if the sample was collected within 12 hours of the suspected dosing and the scenario indicates the sample was collected beyond that timeframe.
TF2K4M	internal standard=mepivacaine
UZHJHF	Diphenhydramine
V4XAKQ	Mepivacaine and Mephobarbital internal standards used.
W68H9G	Promazine used as internal standard for GC/MS screening and confirmatory analysis. Prazepam used as internal standard for GC/MS benzodiazepine screening. GHB-d6 used as internal standard for GC/MS GHB screening.
WZCR36	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
XCZBUF	GC/MS ISTD - Phenyltoloxamine d6-GHB LC/MS-MS ISTD - d3-Hydromorphone d3-Oxycodone d5-Diazepam
XE9KQJ	internal standard: mepivacaine
XHQK4D	screened for urine drug panel and GHB.
XJZPJM	HRAMS i.s. mepivacaine. GCMS i.s. mepivacaine
XPQZUL	Internal Standard: Mepivacaine
XZ7U6E	Chemiluminescence Immunoassay screening technique. Urine screening includes the following at specified cutoffs: Fentanyl 2ng/ml, ABPINACA 2.5ng/ml, Methamphetamine 200ng/ml, Barbiturates 200ng/ml, Benzodiazepines 150ng/ml, Methadone 300ng/ml, Opiates 200ng/ml, Benzoylcegonine 150ng/ml, Oxycodone 50ng/ml, Tramadol 5ng/ml, THC 20ng/ml, TCA 150ng/ml, Amphetamine 200ng/ml, Buprenorphine 1ng/ml, 6MAM 10ng/ml, JWH-018 20ng/ml, Alpha PVP 5ng/ml, UR 144 10ng/ml
YJEF4R	Diphenhydramine LOD 5ng/ml; ISTD Diphenhydramine-d3
ZA74PA	Diphenhydramine: ISTD Diphenhydramine-d3; LOD 5ng/mL
ZFFKXX	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.

Screening Results - Item 4

TABLE 4A

Item Scenario:

A 35 year old male in rehabilitation for alcohol abuse was subject to routine drug testing.

Item Contents and Preparation Concentration: Oxazepam (120 ng/mL)
 Temazepam (80 ng/mL)
 Acetaminophen (70 ng/mL)

WebCode	Screening Results
29UQKC	Oxazepam/Temazepam - Benzodiazepine Class
2G4FXB	Benzodiazepines (class)
33K6QZ	benzodiazepines
372DEY	Oxazepam, Temazepam
3AL8AE	Benzodiazepines
3DY877	Amphetamine, Benzodiazepines
3R2FBF	Benzodiazepines
3V4EL9	Oxazepam Temazepam
46ZY6C	Oxazepam Temazepam
4KGYVB	Benzodiazepines
4M67KD	benzodiazepines
62FC4C	Benzodiazepines
6XGXJ8	Oxazepam Temazepam
74HP6A	Benzodiazepines
76EARA	benzodiazepine - temazepam
7HMTQ4	Temazepam Oxazepam
7QHQQD	Benzodiazepines, temazepam, oxazepam
7RCGMR	Temazepam
7T6AHB	Benzodiazepines
8A4698	Oxazepam Temazepam
8DL4L3	Oxazepam Temazepam

TABLE 4A: Screening Results - Item 4

WebCode	Screening Results
8JQ3YD	Randox Evidence Investigator drug category: BENZ 1
8MA3D8	Benzodiazepine class
8PFKB4	The following group of substance was detected in the urine sample: positive for benzodiazepines
8R8JP2	Benzodiazepines, Amphetamine
8V7UL2	Benzoylcegonine, Benzodiazepines, Amphetamine
9CNDTT	temazepam, oxazepam
9FBVBD	temazepam, oxazepam
9J4WB8	Benzodiazepines
9YZBBZ	benzodiazepines
A2LEJX	Benzodiazepine
A3DB8R	Benzodiazepines - Traquilizers
AAWG6Y	Benzodiazepines
B47LK7	Immunoassay: Benzodiazepines LC/MS/MS & LC-HRMS/MS: oxazepam and temazepam
BMJ7EN	No drugs detected utilizing screening methods.
BRWNW7	benzodiazepines group
C2GEW3	Benzodiazepines
C6GQR3	Benzodiazepines
CW4WEL	Temazepam, Oxazepam
D4H3NX	Benzodiazepines - Oxazepam, Temazepam
D8XACX	Oxazepam and Temazepam
DBYE76	temazepam, oxazepam
DTH8U9	temazepam, oxazepam
E4WNZK	Benzodiazepines 1
EMMZP6	Oxazepam (GC/MS) Temazepam (GC/MS)
F2M227	Benzodiazepines
FDTEUR	Oxazepam, Temazepam
FFKAJK	No drugs detected utilizing screening methods.

TABLE 4A: Screening Results - Item 4

WebCode	Screening Results
FJ7R27	temazepam oxazepam
FJKHMY	Benzodiazepines
FXZJLL	- Benzodiazepine class
GH8RAR	Oxazepam Temazepam
GLTTJY	Benzodiazepines
HDTXUY	Oxazepam, Temazepam
HPMAAX	temazepam, oxazepam, acetaminophen
JFTLPF	Benzodiazepines
JHGTDH	Benzodiazepines
KEEE4X	Benzodiazepine Class detected
KN3AZT	Benzodiazepines
KVJLHZ	No drugs detected utilizing screening methods.
LLPZML	Benzodiazepines
LNGVCF	Benzodiazepines
MKDKTK	Benzodiazepines
MNENMT	oxazepam, temazepam
MYW6FZ	Benzodiazepines
NFETXT	Oxazepam, Temazepam
NH3ZMW	Benzodiazepines
NHHJ8U	Oxazepam, Temazepam, Certain Benzodiazepines
NP3JKL	Amphetamine and Benzodiazepines
PBFT2A	Benzodiazepines
PE2BJU	benzodiazepine class
PFV2P9	Benzodiazepines
PQVR9V	Temazepam, Oxazepam via GC/MS
PRMQLU	benzodiazepines
PVL2HU	benzodiazepines

TABLE 4A: Screening Results - Item 4

WebCode	Screening Results
Q9PRTZ	Benzodiazepines
QEVNEL	Oxazepam Temazepam
QVZVUM	Benzodiazepines
QYFH8T	benzodiazepines (temazepam & oxazepam)
R22LFQ	temazepam and oxazepam
R4N7GN	Benzodiazepine
R8P7J7	Benzodiazepines
RBCN2Q	Benzodiazepines-oxazepam, temazepam
T3QENE	Oxazepam Temazepam
T3VRCB	benzodiazepines
T6HBD9	Oxazepam, temazepam
T7U38A	Benzodiazepines
TF2K4M	benzodiazepines, oxazepam and temazepam
U82PEM	Benzodiazepines
U9DG9P	Benzodiazepines (Benz 1)
UCWGMK	temazepam oxazepam
UZHJHF	Temazepam and oxazepam
V4XAKQ	Temazepam, Oxazepam
VBJ8AD	Benzodiazepine positive screen
VR3ZXG	Oxazepam Temazepam
W68H9G	Benzodiazepines
WZCR36	Benzodiazepines
XCZBUF	Benzodiazepines
XE9KQJ	benzodiazepines
XHQK4D	temazepam, oxazepam
XJZPJM	oxazepam, temazepam

TABLE 4A: Screening Results - Item 4

WebCode	Screening Results
XPQZUL	Certain benzodiazepines Oxazepam Temazepam
XZ7U6E	Benzodiazepine
YJEF4R	Oxazepam, Temazepam
ZA74PA	Benzoylcegonine Oxazepam Temazepam
ZFFKXX	Benzodiazepines

Screening Response Summary for Item 4	Participants: 106
Oxazepam:	43
Temazepam:	45
Acetaminophen:	1
Benzodiazepines:	68
Other Drugs Detected:	6
No Drugs Detected Utilizing Screening Methods:	3

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 4

TABLE 4B

Item Scenario:

A 35 year old male in rehabilitation for alcohol abuse was subject to routine drug testing.

Item Contents and Preparation Concentration: Oxazepam (120 ng/mL)
 Temazepam (80 ng/mL)
 Acetaminophen (70 ng/mL)

What drugs/metabolites were detected in Item 4?

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
29UQKC	Oxazepam	✓			
	Temazepam	✓			
2G4FXB	Oxazepam	✓			
	Temazepam	✓			
33K6QZ	oxazepam	✓			
	temazepam	✓			
372DEY	Oxazepam	✓			
	Temazepam	✓			
3R2FBF	Oxazepam	✓			
	Temazepam	✓			
3V4EL9	Oxazepam	✓			
	Temazepam	✓			
46ZY6C	Oxazepam		95	20%	ug/L
	Temazepam		62	20%	ug/L
4KGYVB	Oxazepam	✓			
	Temazepam	✓			
4M67KD	oxazepam	✓			
	temazepam	✓			
62FC4C	Oxazepam	✓			
	Temazepam	✓			
6XGXJ8	Oxazepam	✓			
	Temazepam	✓			
74HP6A	Oxazepam	✓	Detected		
	Temazepam	✓	Detected		
76EARA	Temazepam	✓			
7HMTQ4	Oxazepam	✓			
	Temazepam	✓			
7QHQGD	Oxazepam	✓			
	Temazepam	✓			
8A4698	Oxazepam	✓			
	Temazepam	✓			

TABLE 4B: Confirmatory Results - Item 4

What drugs/metabolites were detected in Item 4?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
8DL4L3	oxazepam		0.14		mg/l
	temazepam		0.070		mg/l
8JQ3YD	Temazepam	✓			
8MA3D8	Oxazepam	✓			
	Temazepam	✓			
8PFKB4	oxazepam	✓			
	Temazepam	✓			
8R8JP2	Oxazepam		192	87	ng/mL
	Temazepam		96	39	ng/mL
8V7UL2	Oxazepam		167	76	ng/mL
	Temazepam		75	30	ng/mL
9CNDTT	oxazepam	✓			
	temazepam	✓			
9FBVBD	oxazepam	✓			
	temazepam	✓			
9J4WB8	Oxazepam	✓			
	Temazepam	✓			
9YZBBZ	oxazepam	✓			
A2LEJX	Oxazepam	✓			
	Temazepam	✓			
A3DB8R	Oxazepam	✓			
	Tryptamine	✓			
	Tryptophan	✓			
AAWG6Y	Oxazepam	✓			
	Temazepam	✓			
ATNMB4	oxazepam	✓			
	Temazepam	✓			
B47LK7	oxazepam	✓			
	temazepam	✓			
BRWNW7	oxazepam	✓			
	temazepam	✓			
C2GEW3	Oxazepam	✓			
	Temazepam	✓			
C6GQR3	Oxazepam	✓			
	Temazepam	✓			

TABLE 4B: Confirmatory Results - Item 4

What drugs/metabolites were detected in Item 4?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
CW4WEL	Oxazepam	✓			
	Temazepam	✓			
D4H3NX	Oxazepam	✓			
	Temazepam	✓			
D7KVNN	Temazepam	✓			
D8XACX	Oxazepam	✓			
	Temazepam	✓			
DBYE76	oxazepam	✓			
	temazepam	✓			
DTH8U9	oxazepam	✓			
	temazepam	✓			
E4WNZK	Oxazepam	✓			
	Temazepam	✓			
EMMZP6	Oxazepam	✓			
	Temazepam	✓			
F2M227	Oxazepam	✓			
	Temazepam	✓			
FDTEUR	Oxazepam	✓			
	Temazepam	✓			
FFKAJK	No drugs/metabolites detected utilizing confirmatory methods.				
FJ7R27	oxazepam	✓			
	temazepam	✓			
FJKHMV	Oxazepam	✓			
	Temazepam	✓			
FXZJLL	Oxazepam		1.98		ppm
GH8RAR	Oxazepam	✓			
	Temazepam	✓			
GLTTJY	Oxazepam	✓			
	Temazepam	✓			
HDTXUY	Oxazepam		142.37		ng/ml
	Temazepam		83.60		ng/ml
HPMAAX	oxazepam	✓			
	temazepam	✓			
	acetaminophen	✓			

TABLE 4B: Confirmatory Results - Item 4

What drugs/metabolites were detected in Item 4?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
JHGTDH	Oxazepam	✓			
	Temazepam	✓			
KEEE4X	oxazepam	✓			
	temazepam	✓			
KN3AZT	Oxazepam	✓			
	Temazepam	✓			
KVJLHZ	Oxazepam	✓			
LLPZML	oxazepam	✓			
	temazepam	✓			
LZ8RCT	oxazepam	✓			
	Temazepam	✓			
MNENMT	oxazepam	✓			
	temazepam	✓			
MYW6FZ	Oxazepam	✓			
	Temazepam	✓			
NFETXT	Oxazepam		242		ng/mL
	Temazepam		195		ng/mL
NH3ZMW	Oxazepam	✓			
	Temazepam	✓			
NHHJ8U	Oxazepam	✓			
	Temazepam	✓			
PE2BJU	oxazepam	✓			
	temazepam	✓			
PQVR9V	Oxazepam	✓			
	Temazepam	✓			
PRMQLU	oxazepam	✓			
	temazepam	✓			
PTZKZ9	No drugs/metabolites detected utilizing confirmatory methods.				
PVL2HU	oxazepam	✓			
	temazepam	✓			
QAZUGK	oxazepam	✓			
	Temazepam	✓			
QEVNEL	Oxazepam	✓			
	Temazepam	✓			

TABLE 4B: Confirmatory Results - Item 4

What drugs/metabolites were detected in Item 4?					
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
QJBV3K	oxazepam	✓			
	Temazepam	✓			
QVZVUM	Oxazepam	✓			
	Temazepam	✓			
QYFH8T	oxazepam	✓			
	temazepam	✓			
R22LFQ	oxazepam	✓			
	temazepam	✓			
R4N7GN	Oxazepam	✓			
	Temazepam	✓			
R8P7J7	Oxazepam		91.68		ng/mL
	Temazepam		63.11		ng/mL
RBCN2Q	oxazepam	✓			
	temazepam	✓			
T3QENE	Oxazepam	✓			
	Temazepam	✓			
T3VRCB	oxazepam	✓			
	temazepam	✓			
T6HBD9	Oxazepam	✓			
	Temazepam	✓			
T7U38A	Oxazepam	✓			
	Temazepam	✓			
TF2K4M	oxazepam	✓			
	temazepam	✓			
U9DG9P	Oxazepam	✓			
	Temazepam	✓			
UCWGMK	oxazepam	✓			
	temazepam	✓			
UZHJHF	oxazepam	✓			
	Temazepam	✓			
V4XAKQ	Temazepam	✓			
VBJ8AD	Oxazepam	✓			
	Temazepam	✓			
VR3ZXG	Oxazepam	✓			
	Temazepam	✓			

TABLE 4B: Confirmatory Results - Item 4

What drugs/metabolites were detected in Item 4?				
WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty Units
W68H9G	Oxazepam	✓		
	Temazepam	✓		
XCZBUF	oxazepam	✓		
	temazepam	✓		
XE9KQJ	Oxazepam	✓		
	Temazepam	✓		
XJZPJM	oxazepam	✓		
	temazepam	✓		
XPQZUL	Oxazepam	✓		
	Temazepam	✓		
YJEF4R	Oxazepam	✓		
	Temazepam	✓		
ZA74PA	Oxazepam	✓		
	Temazepam	✓		

Confirmatory Response Summary for Item 4	Participants: 95
Oxazepam: 89	
Temazepam: 89	
Acetaminophen: 1	
Other Identified Drugs/Metabolites: 2	
No Drugs/Metabolites Detected Utilizing Confirmatory Methods: 2	

Total number of confirmatory responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Raw Data - Item 4

TABLE 4C

Item 4 Raw Data - Oxazepam
Preparation concentration: 120 ng/mL

WebCode	List of Raw Data determinations (ng/mL)			
46ZY6C	96.750	93.680		
8R8JP2	192.00	199.00		
8V7UL2	172.57	167.90		
FXZJL	415.00			
HDTXUY	141.14	143.60		
NFETXT	271.00	246.00	228.00	223.00
R8P7J7	86.435	96.930		

Statistical Analysis for Item 4 - Oxazepam

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

TABLE 4C: Raw Data - Item 4

Item 4 Raw Data - Temazepam
Preparation concentration: 80 ng/mL

WebCode	List of Raw Data determinations (ng/mL)			
46ZY6C	62.040	61.650		
8R8JP2	96.000	99.000		
8V7UL2	81.350	75.100		
HDTXUY	82.520	84.690		
NFETXT	215.00	201.00	184.00	181.00
R8P7J7	60.109	66.120		

Statistical Analysis for Item 4 - Temazepam

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

TABLE 4C: Raw Data - Item 4
Item 4 Raw Data - Acetaminophen
Preparation concentration: 70 ng/mL

WebCode List of Raw Data determinations (ng/mL)

No Raw Data results were reported for this Drug/Analyte for Item 4.

Statistical Analysis for Item 4 - Acetaminophen

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

Reporting Procedures - Item 4

TABLE 4D - Item 4

WebCode	Quantitative Reporting Procedures
46ZY6C	The mean of duplicate/several determinations.
8DL4L3	A single determination.
8R8JP2	Lowest of duplicate samples, truncated
8V7UL2	The lowest of the duplicates
FXZJL	The mean of duplicate/several determinations.
HDTXUY	The mean of duplicate/several determinations.
NFETXT	The mean of duplicate/several determinations.
R8P7J7	The mean of duplicate/several determinations.

Response Summary for Item 4	Participants: 8
A single determination:	1 (12.5%)
The mean of duplicate/several determinations:	5 (62.50%)
Other:	2 (25.0%)

Methods of Analysis - Item 4

TABLE 4E - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
29UQKC	Immunoassay GC/MS	✓ ✓	✓	
2G4FXB	Immunoassay GC/MS	✓ ✓	✓	
33K6QZ	LC/MS/MS	✓	✓	
372DEY	LC/MS/MS	✓	✓	
3AL8AE	Immunoassay	✓		
3DY877	Immunoassay	✓		
3R2FBF	Immunoassay LC/MS/MS	✓	✓	
3V4EL9	LC-QTOF-MS	✓	✓	
46ZY6C	Immunoassay GC/MS LC/MS/MS LC-QTOF	✓ ✓ ✓	✓	✓
4KGYVB	Immunoassay GC/NPD GC/MS LC/MS/MS	✓ ✓	✓ ✓	
4M67KD	Immunoassay LC/MS/MS LC-QTOF-MS	✓	✓ ✓	
62FC4C	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
6XGXJ8	LC-QTOF-MS LC/MS/MS	✓	✓	
74HP6A	Immunoassay GC/MS	✓	✓	
76EARA	Immunoassay GC/MS	✓	✓	
7HMTQ4	Orbitrap-LC/MS LC/MS LC/MS/MS	✓ ✓	✓	

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
7QHQGD	Immunoassay	✓		
	LC/MS	✓	✓	
	GC/MS		✓	
	LC-QExactive		✓	
7RCGMR	GC/MS	✓		
7T6AHB	Immunoassay	✓		
8A4698	LC/MS/MS	✓	✓	
8DL4L3	LC/MS/MS			✓
8JQ3YD	Immunoassay	✓		
	GC/MS		✓	
8MA3D8	Immunoassay	✓		
	GC/MS	✓	✓	
8PFKB4	GC/MS	✓	✓	
8R8JP2	Immunoassay	✓		
	LC/MS/MS		✓	✓
8V7UL2	Immunoassay	✓		
	LC/MS/MS		✓	✓
9CNDTT	LC/MS/MS	✓	✓	
9FBVBD	GC/MS	✓	✓	
	LC-HRMS/MS	✓	✓	
9J4WB8	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
9YZBBZ	Immunoassay	✓		
	GC/MS		✓	
A2LEJX	Immunoassay	✓		
	GC/MS	✓	✓	
A3DB8R	GC/MS	✓	✓	
AAWG6Y	Immunoassay	✓		
	GC/MS	✓	✓	
ATNMB4	GC/MS		✓	
B47LK7	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	LC-HRMS/MS		✓	
BMJ7EN	Immunoassay	✓		

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
BRWNW7	Immunoassay LC/MS/MS	✓	✓	
C2GEW3	Immunoassay GC/MS	✓ ✓	✓	
C6GQR3	Immunoassay GC/MS	✓ ✓	✓	
CW4WEL	LC-QTOF-MS	✓	✓	
D4H3NX	Immunoassay GC/MS	✓ ✓	✓	
D7KVNN	LC-QTOF		✓	
D8XACX	LC/MS/MS GC/MS Rapid Chromatographic Immunoassay	✓ ✓	✓	
DBYE76	LC-HRMS/MS	✓	✓	
DTH8U9	LC-HRMS/MS GC/MS	✓	✓ ✓	
E4WNZK	Immunoassay LC-QTOF GC/MS LC-QTOF	✓ ✓	✓ ✓	
EMMZP6	Immunoassay GC/MS	✓ ✓	✓	
F2M227	Immunoassay LC/MS/MS	✓	✓	
FDTEUR	Immunoassay GC/MS	✓ ✓	✓	
FFKAJK	LC/MS/MS	✓	✓	✓
FJ7R27	LC-HRMS/MS GC/MS	✓	✓	
FJKHMV	Immunoassay GC/MS	✓ ✓	✓	
FXZJL	GC/MS	✓	✓	✓
GH8RAR	Immunoassay LC-QTOF LC/MS/MS	✓ ✓	✓	

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
GLTTJY	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
HDTXUY	LC/MS/MS	✓	✓	✓
HPMAAX	LC-QTOF-MS	✓	✓	
	LC/MS/MS		✓	
JFTLPF	Immunoassay	✓		
JHGTDH	Immunoassay	✓		
	GC/MS		✓	
KEEE4X	Immunoassay	✓		
	LC/MS/MS		✓	
	GC/MS	✓	✓	
KN3AZT	Immunoassay	✓		
	GC/MS	✓	✓	
KVJLHZ	Immunoassay	✓		
	GC/MS		✓	
LLPZML	Immunoassay	✓		
	GC/MS	✓	✓	
LNGVCF	Immunoassay	✓		
LZ8RCT	GC/MS		✓	
MKDGTK	Immunoassay	✓		
MNENMT	GC/MS	✓	✓	
	LC/MS/MS	✓		
MYW6FZ	Immunoassay	✓		
	LC/MS/MS		✓	
NFETXT	Immunoassay	✓		
	LC-QTOF		✓	
	LC/MS/MS		✓	✓
NH3ZMW	Immunoassay	✓		
	LC/MS/MS		✓	
NHHJ8U	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	LC-HRMS/MS		✓	
NP3JKL	Immunoassay	✓		
PBFT2A	Immunoassay	✓		

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
PE2BJU	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
PFV2P9	Immunoassay	✓		
PQVR9V	Immunoassay GC/MS	✓ ✓	✓	
PRMQLU	Immunoassay LC/MS/MS LC-HRMS/MS	✓	✓ ✓	
PTZKZ9	GC/MS		✓	
PVL2HU	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
Q9PRTZ	Immunoassay	✓		
QAZUGK	GC/MS		✓	
QEVNEL	LC-QTOF-MS LC/MS/MS	✓	✓	
QJBV3K	GC/MS		✓	
QVZVUM	Immunoassay GC/MS	✓ ✓	✓	
QYFH8T	Immunoassay LC/MS/MS LC-HRMS/MS	✓ ✓	✓ ✓	
R22LFQ	Immunoassay LC/MS/MS LC-HRMS/MS	✓ ✓	✓ ✓	
R4N7GN	Immunoassay GC/MS LC-QTOF-MS	✓	✓ ✓	
R8P7J7	ELISA LC/MS/MS	✓	✓	✓
RBCN2Q	Immunoassay LC/MS/MS LC-HRMS/MS	✓ ✓	✓ ✓	
T3QENE	Immunoassay GC/MS	✓ ✓	✓	
T3VRCB	Immunoassay GC/MS	✓	✓	

TABLE 4E: Methods of Analysis - Item 4

WebCode	Method	Screening	Confirmatory	Quantitation
T6HBD9	LC/MS/MS	✓	✓	
T7U38A	Immunoassay GC/MS	✓	✓	
TF2K4M	Immunoassay LC/MS/MS GC/MS	✓ ✓ ✓	✓ ✓	
U82PEM	Immunoassay	✓		
U9DG9P	Immunoassay LC/MS/MS	✓	✓	
UCWGMK	LC/MS/MS	✓	✓	
UZHJHF	LC/MS	✓	✓	
V4XAKQ	LC-HRMS/MS	✓	✓	
VBJ8AD	Immunoassay GC/MS	✓ ✓	✓	
VR3ZXG	LC-QTOF-MS LC/MS/MS	✓	✓	
W68H9G	Immunoassay GC/MS	✓ ✓	✓	
WZCR36	Immunoassay	✓		
XCZBUF	Immunoassay GC/MS LC/MS/MS	✓ ✓	✓	
XE9KQJ	Immunoassay LC/MS/MS GC/MS	✓ ✓	✓ ✓	
XHQK4D	LC/MS/MS	✓		
XJZPJM	hrams GC/MS	✓	✓	
XPQZUL	Immunoassay LC/MS LC-HRMS/MS	✓	✓ ✓	
XZ7U6E	Immunoassay	✓		
YJEF4R	LC/MS/MS	✓	✓	
ZA74PA	LC/MS/MS	✓	✓	
ZFFKXX	Immunoassay	✓		

Response Summary for Item 4 - Methods of Analysis		Participants: 112		
	Screening	Confirmatory	Quantitation	
Immunoassay:	73	0	0	
GC/MS:	28	52	1	
LC/MS:	3	3	0	
LC/MS/MS:	20	44	8	
Other:	19	20	0	

Additional Comments for Item 4

TABLE 4F

WebCode	Item Comments
29UQKC	Drug screen: screening/confirmation - Promazine - internal standard. Benzodiazepine Confirmation: Prazepam - internal standard
2G4FXB	Promazine (ISTD) - Drug Screen for Urine. Prazepam (ISTD) - Benzodiazepine in Urine
3AL8AE	Benzodiazepines cutoff is 300 ng/mL. Creatinine is normal.
3R2FBF	The cut-off value of temazepam and oxazepam is 10 ng/ml for LC/MS/MS
3V4EL9	Estazolam was used as internal standard
46ZY6C	Internal standard for Temazepam quantitation was D5 Temazepam. Internal standard for Oxazepam quantitation was D5 Oxazepam.
4M67KD	Internal Standard-Mepivacaine. Temazepam Limit of detection=0.025 mg/L
6XGXJ8	Oxazepam LOD set at 50 ng/mL. Temazepam LOD set at 50 ng/mL
74HP6A	The Toxicology laboratory uses an immunoassay which screens for the following six drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP.
7RCGMR	Liquid-liquid extraction (H+/OH-) with DCM followed by derivatisation with BSTFA
7T6AHB	Benzodiazepines assay cutoff: 300 ng/mL. Creatinine normal
8MA3D8	Promazine was used as an internal standard for the Drug Screen analysis and prazepam was used as an internal standard for the Benzodiazepine confirmation analysis.
8R8JP2	Basic Drug screen ran as a result of Amphetamine presumptive positive came back not detected. The item was analyzed for the following drugs utilizing the listed methods: Immunoassay Drug Screen (Enzyme Linked Immunosorbent Assay- ELISA): amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylecgonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem. Basic Drug Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: amphetamine, diphenhydramine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, LSD. Qualitatively: ephedrine/pseudoephedrine, psilocin. Benzodiazepines Confirmation (Liquid Chromatography/Tandem Mass Spectrometry LC/MS/MS): Quantitatively: 7-aminoclonazepam, alprazolam, chlordiazepoxide, clonazepam, diazepam, flunitrazepam, lorazepam, nordiazepam, oxazepam, temazepam, zolpidem Qualitatively: 7-aminoflunitrazepam, estazolam, etizolam, midazolam, nitrazepam, triazolam, zopiclone
8V7UL2	This sample screened presumptive positive for benzoylecgonine, however our laboratory is not currently able to confirm this compound. Therefore, confirmatory testing for benzoylecgonine was not performed. This sample screened presumptive positive for amphetamine and confirmatory testing was performed, however this analyte was not detected. The limit of quantitation for amphetamine is 5 ng/mL.
9CNDTT	screening performed 4/3/24, confirmatory testing on 4/5/24
9FBVBD	Internal standard - Mepivacaine. Artifacts - caffeine
9J4WB8	The Internal standard was used is Codeine D3.
9YZBBZ	Confirmatory ISTD: NPA and SKF. Temazepam appeared present, but was below reporting threshold. our current GC/MS method is not always as sensitive for benzodiazepines and our LC/MS-MS method that is used for benzodiazepines is only validated for blood.
ATNMB4	Internal standard: Flurazepam. Sample preparation: L/L extraction. The final extract is derivatized with BSTFA and analyzed by GC/MS

TABLE 4F: Additional Comments for Item 4

WebCode	Item Comments
B47LK7	Internal Standard for LC/MS/MS & LC-HRMS/MS: mepivacaine
BMJ7EN	Immunoassay cutoff for benzodiazepines is 300 ng/mL.
CW4WEL	IS: Triazolam-D4; LOD: 10 ng/mL.
D8XACX	iCassette (THC) test device was used to screen for THC, referred to in 4-5 as rapid Chromatographic immunoassay.
DBYE76	IS: mepivacaine, mephobarbital
DTH8U9	LC-HRMS/MS internal standards: mepivacaine, mephobarbital. GC/MS internal standard: mepivacaine
EMMZP6	Hexobarbital, n-Propylamphetamine, and Mepivacaine were used as GC/MS internal standards. Lab does not offer ethanol testing in urine samples.
FFKAJK	Panel includes only the following analytes: Cyclobenzaprine, Imipramine, Mitragynine, Zolpidem, Phencyclidine
FXZJLL	- Acetonitrile was detected in the urine sample (GCMS-Hs) - L- Tryptophan was detected in the urine sample. - Paracetamol was detected in the urine sample. - Hydroquinone detected. - Ethyl-3-indoleacetate was detected by GCMS - Naringenin detected. - Methylthioadenosine detected. - Temazepam- D5 was used an internal standard for GMs quantification
HPMAAX	LC/MS/MS was the confirmatory method for the temazepam and oxazepam. LC-QTOF-MS was the screening and the confirmatory method for the acetaminophen.
KEEE4X	Internal Standard: Mepivacaine
KN3AZT	Internal Standards used: Promazine, Prazepam.
KVJLHZ	LOD for benzos is 300ng/mL on ELISA
LNGVCF	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
MKDKTK	Benzodiazepine urine confirmation method unavailable.
NFETXT	Caffeine was also detected using targeted analysis on LCMSMS.
NHHJ8U	Internal Standards: Mepivacaine and Mepicavaine/Mephobarbital
NP3JKL	This screened presumptive positive for amphetamine and benzodiazepines. However, I am not qualified to confirm the presence of these two substances. The immunoassay tests for the following drugs: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine/benzoylcegonine, cannabinoids, carisoprodol, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine (PCP), tramadol, zolpidem
PE2BJU	Mepivacaine was the internal standard used for GC/MS and LC/MS/MS methods.
PFV2P9	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
PQVR9V	N-Propylamphetamine, Mepivacaine, and Hexobarbital were used as Internal Standards. This lab does not offer urine ethanol testing.
PRMQLU	mepivacaine used as internal standard
PTZKZ9	Internal Standard: SKF-525A
PVL2HU	mepivacaine internal standard used for gcms and lcmsms analysis

TABLE 4F: Additional Comments for Item 4

WebCode	Item Comments
QAZUGK	Internal standard: Flurazepam
QEVNEL	Oxazepam LOD set at 50 ng/mL. Temazepam LOD set at 50 ng/mL
QJBV3K	Tetracosane is the internal standard
QVZVUM	Internal standard used for drug screen was promazine and benzodiazepine confirmation was prazepam.
QYFH8T	Internal Standard - mepivacaine
R22LFQ	Internal Standard: mepivacaine
RBCN2Q	Internal Standard-Mepivacaine/Nalorphine, Mepivacaine, Mephobarbital
RU3ZQB	Item 4 not analyzed.
TF2K4M	Liquid Chromatography-High Resolution Mass Spectrometry/Mass Spectrometry. internal standard=mepivacaine
U82PEM	No methodology available for Benzodiazepines confirmatory analysis.
V4XAKQ	Mepivacaine and Mephobarbital internal standards used.
VR3ZGX	Oxazepam LOD set at 50 ng/mL. Temazepam LOD set at 50 ng/mL
W68H9G	Promazine used as internal standard for GC/MS screening analysis. Prazepam used as internal standard for GC/MS benzodiazepine confirmatory analysis.
WZCR36	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
XCZBUF	GC/MS ISTD - Phenyltoloxamine LC/MS-MS ISTD - d5-Diazepam
XE9KQJ	internal standard: mepivacaine
XHQK4D	urine benzodiazepine method not validated at this time
XJZPJM	HRAMS i.s. mepivacaine. GCMS i.s. mepivacaine
XPQZUL	Internal Standard: Mepivacaine, Mepivacaine/ Mephobarbital
XZ7U6E	Chemiluminescence Immunoassay screening technique
YJEF4R	Oxazepam LOD 10ng/ml; ISTD Oxazepam-d5. Temazepam LOD 5ng/ml; ISTD Temazepam-d5
ZA74PA	Oxazepam: ISTD Oxazepam-d5; LOD 10 ng/mL. Temazepam: ISTD Temazepam-d5; LOD 5 ng/mL
ZFFKXX	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.

Additional Test Comments

TABLE 5

WebCode	Additional Comments
3DY877	No confirmation testing was performed as I am only qualified and trained in ELISA screening.
9CNDTT	samples stored frozen prior to analysis
AQ24A7	Did not test items 2-4.
CW4WEL	This identification method involves a broad-spectrum extraction for drugs, utilizing positive ion mode HPLC-QToF for confirmation testing.
FFKAJK	Item # 4 from this PT set was empty upon arrival. [Name] and [Name] spoke with [Name] over the phone on 3-14-24 around 3 pm CT. [Name] will send replacement set containing exact all 4 exact samples as the original set. [Laboratory Name] will reject the original batch and accession the new replacement set containing all 4 samples. The date listed above represents the 2nd set of samples received.
GCF2RF	Only item 1 was tested at the [Laboratory] site.
LNGVCF	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
PFV2P9	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
QVZVUM	Only reported drugs following the [State] Policy Toxicology Drug Panel.
W68H9G	Results reported using laboratory drug panel guidelines.
WZCR36	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.
XZ7U6E	Chemiluminescence Immunoassay screening technique Urine screening includes the following at specified cutoffs: Fentanyl 2ng/ml ABPINACA 2.5ng/ml Methamphetamine 200ng/ml Barbiturates 200ng/ml Benzodiazepines 150ng/ml Methadone 300ng/ml Opiates 200ng/ml Benzoyllecgonine 150ng/ml Oxycodone 50ng/ml Tramadol 5ng/ml THC 20ng/ml TCA 150ng/ml Amphetamine 200ng/ml Buprenorphine 1ng/ml 6MAM 10ng/ml JWH-018 20ng/ml Alpha PVP 5ng/ml UR 144 10ng/ml
ZFFKXX	All substances detected using immunoassay testing, cutoffs are listed below. 6AM-10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL.

-End of Report-
(Appendix may follow)

Collaborative Testing Services ~ Forensic Testing Program

Test No. 24-5671: Urine Drug Analysis

DATA MUST BE SUBMITTED BY **May 13, 2024, 11:59 p.m. EDT** TO BE INCLUDED IN THE REPORT

Participant Code: U1234K

WebCode: AAHAK3

Scenario:

Investigators have submitted four urine specimens from four separate cases for your analysis. Using your laboratory's procedures, analyze each sample and report the presence of any drugs and/or metabolites.

Case 1: A 49 year old female was pulled over in the early morning for swerving between lanes. The officer noted slowed speech and drowsiness. A urine sample was collected for analysis two hours later.

Case 2: A 26 year old male was arrested for attempted robbery of a local drug store. Upon arrest he displayed agitated behavior and was sweating profusely. Urine was collected within 4 hours of arrest.

Case 3: A 22 year old female visited the police station after suspecting she was the victim of a drug-facilitated sexual assault. She was at a party the night before where she encountered a male who provided her with at least two alcoholic beverages. The victim described her symptoms as: feeling unusual, unable to focus or keep her eyes open, difficulty speaking, body incoordination, drowsiness, and memory loss. A urine sample was collected within 72 hours.

Case 4: A 35 year old male in rehabilitation for alcohol abuse was subject to routine drug testing.

-Samples may contain methanol and acetonitrile as artifacts from production.

***PLEASE NOTE** The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly.*

Items Submitted (Sample Pack UDRG):

Item 1: Urine sample from Case 1

Item 2: Urine sample from Case 2

Item 3: Urine sample from Case 3

Item 4: Urine sample from Case 4

Screening Results for Item 1:

- 1-1). Please indicate the screening results for Item 1.
- No drugs detected utilizing screening methods.
 - Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 1:

- 1-2). Was confirmatory analysis performed for this item? Yes No
- 1-3). What drugs/metabolites were detected in Item 1? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.
- No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
<input style="width: 90%;" type="text"/>	<input type="checkbox"/>	<input style="width: 80%;" type="text"/>	<input style="width: 80%;" type="text"/>	(<input style="width: 40%;" type="text"/>)
Date(s) Analysis Performed on Analyte: <input style="width: 80%;" type="text"/>				
Raw Data (ng/mL):				
<input style="width: 80%;" type="text"/>	<input style="width: 80%;" type="text"/>	<input style="width: 80%;" type="text"/>	<input style="width: 80%;" type="text"/>	<input style="width: 80%;" type="text"/>

- 1-4). If quantitative analysis was performed, are the reported concentrations above
- A single determination? The mean of duplicate / several determinations?
 - Other? (Specify):
- 1-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.
- Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
<input style="width: 90%;" type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

- 1-6). **Additional Comments for Item 1**
Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.

Screening Results for Item 2:

- 2-1). Please indicate the screening results for Item 2.
- No drugs detected utilizing screening methods.
 - Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 2:

- 2-2). Was confirmatory analysis performed for this item? Yes No
- 2-3). What drugs/metabolites were detected in Item 2? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.
- No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
<input style="width: 90%;" type="text"/>	<input type="checkbox"/>	<input style="width: 80%;" type="text"/>	<input style="width: 80%;" type="text"/>	(<input style="width: 40%;" type="text"/>)
Date(s) Analysis Performed on Analyte: <input style="width: 80%;" type="text"/>				
Raw Data (ng/mL):				
<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>

- 2-4). If quantitative analysis was performed, are the reported concentrations above
- A single determination? The mean of duplicate / several determinations?
 - Other? (Specify):
- 2-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.
- Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
<input style="width: 90%;" type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

- 2-6). **Additional Comments for Item 2**
Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.

Screening Results for Item 3:

- 3-1). Please indicate the screening results for Item 3.
- No drugs detected utilizing screening methods.
 - Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 3:

- 3-2). Was confirmatory analysis performed for this item? Yes No
- 3-3). What drugs/metabolites were detected in Item 3? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.
- No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
<input style="width: 90%;" type="text"/>	<input type="checkbox"/>	<input style="width: 80%;" type="text"/>	<input style="width: 80%;" type="text"/>	(<input style="width: 50%;" type="text"/>)
Date(s) Analysis Performed on Analyte: <input style="width: 80%;" type="text"/>				
Raw Data (ng/mL):				
<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>	<input style="width: 15%;" type="text"/>

- 3-4). If quantitative analysis was performed, are the reported concentrations above
- A single determination? The mean of duplicate / several determinations?
 - Other? (Specify):
- 3-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.
- Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
<input style="width: 90%;" type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

- 3-6). **Additional Comments for Item 3**
Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.

Screening Results for Item 4:

- 4-1). Please indicate the screening results for Item 4.
- No drugs detected utilizing screening methods.
 - Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 4:

- 4-2). Was confirmatory analysis performed for this item? Yes No
- 4-3). What drugs/metabolites were detected in Item 4? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.
- No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
<input type="text"/>	<input type="checkbox"/>	<input type="text"/>	<input type="text"/>	(<input type="text"/>)
Date(s) Analysis Performed on Analyte: <input type="text"/>				
Raw Data (ng/mL):				
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

- 4-4). If quantitative analysis was performed, are the reported concentrations above
- A single determination?
 - The mean of duplicate / several determinations?
 - Other? (Specify):
- 4-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.
- Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

- 4-6). Additional Comments for Item 4
Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.

Date Samples Received:

Additional Comments on Test

Please note: Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.

RELEASE OF DATA TO ACCREDITATION BODIES

The Accreditation Release is accessed by pressing the "Continue to Final Submission" button online and can be completed at any time prior to submission to CTS.

CTS submits external proficiency test data directly to ANAB and/or A2LA. Please select one of the following statements to ensure your data is handled appropriately.

- This participant's data is intended for submission to ANAB and/or A2LA. (Accreditation Release section below must be completed.)
- This participant's data is not intended for submission to ANAB and/or A2LA.

Have the laboratory's designated individual complete the following steps **only if your laboratory is accredited in this testing/calibration discipline** by one or more of the following Accreditation Bodies.

Step 1: Provide the applicable Accreditation Certificate Number(s) for your laboratory.

ANAB Certificate No.

A2LA Certificate No.

Step 2: Complete the Laboratory Identifying Information in its entirety.

Authorized Contact Person and Title

Laboratory Name

Location (City/State)